U.S. patent application number 11/172341 was filed with the patent office on 2005-12-08 for methods for genomic analysis.
This patent application is currently assigned to Perlegen Sciences, Inc.. Invention is credited to Berno, Anthony J., Cox, David R., Hinds, David A., Patil, Nila.
Application Number | 20050272086 11/172341 |
Document ID | / |
Family ID | 27501283 |
Filed Date | 2005-12-08 |
United States Patent
Application |
20050272086 |
Kind Code |
A1 |
Patil, Nila ; et
al. |
December 8, 2005 |
Methods for genomic analysis
Abstract
The present invention relates to methods for identifying
variations that occur in the human genome and relating these
variations to the genetic basis of disease and drug response. In
particular, the present invention relates to identifying individual
SNPs, determining SNP haplotype blocks and patterns, and, further,
using the SNP haplotype blocks and patterns to dissect the genetic
bases of disease and drug response. The methods of the present
invention are useful in whole genome analysis.
Inventors: |
Patil, Nila; (Woodside,
CA) ; Cox, David R.; (Belmont, CA) ; Berno,
Anthony J.; (San Jose, CA) ; Hinds, David A.;
(Mountain View, CA) |
Correspondence
Address: |
PERLEGEN SCIENCES, INC.
LEGAL DEPARTMENT
2021 STIERLIN COURT
MOUNTAIN VIEW
CA
94043
US
|
Assignee: |
Perlegen Sciences, Inc.
Mountain View
CA
|
Family ID: |
27501283 |
Appl. No.: |
11/172341 |
Filed: |
June 29, 2005 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11172341 |
Jun 29, 2005 |
|
|
|
10106097 |
Mar 26, 2002 |
|
|
|
60280530 |
Mar 30, 2001 |
|
|
|
60313264 |
Aug 17, 2001 |
|
|
|
60327006 |
Oct 5, 2001 |
|
|
|
60332550 |
Nov 26, 2001 |
|
|
|
Current U.S.
Class: |
435/6.11 |
Current CPC
Class: |
G16B 40/00 20190201;
Y10T 436/143333 20150115; G16B 40/10 20190201; G16B 30/00 20190201;
C12Q 1/6827 20130101 |
Class at
Publication: |
435/006 |
International
Class: |
C12Q 001/68 |
Claims
What is claimed is:
1. A method for identifying pharmacogenomic-related genetic loci,
comprising: a) determining SNP haplotype patterns comprising a set
of SNP alleles from a plurality of individuals in a first
population, wherein said individuals in said first population react
in a particular manner to administration of a substance; b)
determining SNP haplotype patterns comprising a set of SNP alleles
from a plurality of individuals in a second population, wherein
said individuals in said second population do not react in said
particular manner to administration of said substance; and c)
comparing frequencies of said SNP haplotype patterns from said
individuals in said first population with frequencies from said SNP
haplotype patterns of said individuals in said second population,
wherein genomic locations of SNP haplotype patterns that exhibit a
difference in said frequencies are pharmacogenomic-related genetic
loci.
2. The method of claim 1, wherein said identifying is performed
without a priori knowledge of a sequence or location of said
pharmacogenomic-related genetic loci.
3. The method of claim 1, wherein said SNP haplotype patterns are
determined in at least 10 individuals in at least one of said first
population or said second population.
4. The method of claim 1, wherein said SNP haplotype patterns
recited in steps a) and b) are determined using informative
SNPs.
5. The method of claim 1, wherein in step a) and step b) said
determining of SNP haplotype patterns is performed using pooled
genomic DNA samples from individuals of said first population and
said second population, respectively.
6. The method of claim 1, further comprising using said
pharmacogenomic-related genetic loci as diagnostic markers for a
given condition or phenotypic trait.
7. The method of claim 6, wherein said diagnostic markers are
included in a kit for diagnosis of a disease, disease
susceptibility, or treatment response.
8. The method of claim 7, wherein said kit further comprises means
for detecting a presence or absence of said pharmacogenomic-related
genetic loci in a sample of genomic DNA from a patient.
9. The method of claim 1 further comprising building a baseline of
SNP haplotype patterns, wherein said building a baseline of SNP
haplotype patterns comprises: identifying genetic variations in a
plurality of individuals; identifying at least some of said genetic
variations in individuals that occur with at least some other of
said genetic variations; grouping said some of said variations in
individuals that occur with said some other of said genetic
variations into SNP haplotype blocks; identifying SNP haplotype
patterns in said SNP haplotype blocks; and adding said SNP
haplotype patterns in said SNP haplotype blocks to said baseline of
SNP haplotype patterns, thereby building said baseline of SNP
haplotype patterns, wherein said baseline of SNP haplotype patterns
comprises said SNP haplotype patterns from said individuals in said
second population, and wherein said baseline of SNP haplotype
patterns further comprises said SNP haplotype patterns from said
individuals in said first population.
10. The method of claim 1 further comprising building a baseline of
SNP haplotype patterns, wherein said building a baseline of SNP
haplotype patterns comprises: determining a sequence of an
organism; scanning additional individuals of said organism for
variants from said sequence; identifying some of said variants that
occur with others of said variants in a first SNP haplotype block;
identifying some of said variants that occur with others of said
variants in a second SNP haplotype block; identifying SNP haplotype
patterns in said first SNP haplotype block and said second SNP
haplotype block; and adding said SNP haplotype patterns in said
first SNP haplotype block and said second SNP haplotype block to
said baseline of SNP haplotype patterns, thereby building said
baseline of SNP haplotype patterns, wherein said baseline of SNP
haplotype patterns comprises said SNP haplotype patterns from said
individuals in said second population, and wherein said baseline of
SNP haplotype patterns further comprises said SNP haplotype
patterns from said individuals in said first population.
11. A method for identifying pharmacogenomic-related loci without a
priori knowledge of a sequence or location of said
pharmacogenomic-related loci, comprising: identifying genetic
variations in a plurality of individuals; identifying at least some
of said genetic variations that occur with at least some others of
said genetic variations; genotyping a subset of said at least some
of said genetic variations that occur with at least some others of
said genetic variations in both a case population and a control
population to generate a data set of genotypes, wherein said case
population consists of individuals who exhibit a particular
response to a treatment and said control population consists of
individuals who do not exhibit said particular response; based on
said data set of genotypes, computing a genotype frequency in said
case population and a genotype frequency in said control population
for each of said subset; and identifying as pharmacogenomic-related
loci a set of genetic variants for which said genotype frequency in
said case population is different than said genotype frequency in
said control population.
12. The method of claim 11, wherein said genetic variants are
SNPs.
13. The method of claim 11, wherein one or more of said
pharmacogenomic related loci occur within one or more coding
regions of a genome.
14. The method of claim 11, wherein one or more of said
pharmacogenomic related loci occur within one or more noncoding
regions of a genome.
15. The method of claim 11, wherein said individuals are
mammals.
16. The method of claim 11, wherein said genotyping is performed
using probes bound to a solid surface.
17. The method of claim 11, further comprising using said
pharmacogenomic-related loci for a purpose selected from the group
consisting of: testing of a candidate agent; stratification of a
population for clinical studies; development of a gene therapy; and
use as a drug discovery target.
18. A method for identifying pharmacogenomic-related loci without a
priori knowledge of a sequence or location of said
pharmacogenomic-related loci, comprising: determining a sequence of
an organism; scanning additional individuals of said organism for
genetic variants from said sequence; identifying a first subset of
said genetic variants that occur with others of said genetic
variants in a first group; identifying a second subset of said
genetic variants that occur with others of said genetic variants in
a second group; and using some, but not all, of said genetic
variants in said first and second groups in an association study to
identify which of said genetic variants is correlated with a
phenotypic state, wherein said phenotypic state is a response to a
pharmaceutical treatment, and further wherein genetic variants that
are correlated with said phenotypic state are
pharmacogenomic-related loci.
19. The method of claim 18, wherein said genetic variants are
SNPs.
20. The method of claim 18, wherein one or more of said
pharmacogenomic related loci occur within one or more coding
regions of a genome.
21. The method of claim 18, wherein one or more of said
pharmacogenomic related loci occur within one or more noncoding
regions of a genome.
22. The method of claim 18, wherein said sequence of an organism
comprises at least 10,000 bases of genomic DNA of said
organism.
23. The method of claim 18, wherein said organism is a mammal.
24. The method of claim 18, further comprising using said
pharmacogenomic-related loci for a purpose selected from the group
consisting of: testing of a candidate agent; stratification of a
population for clinical studies; development of a gene therapy; and
use as a drug discovery target.
25. A method for determining pharmacogenomic-related genetic loci
without a priori knowledge of a sequence or location of said
pharmacogenomic-related genetic loci, comprising: a) determining
control genotypes, wherein said control genotypes are genotypes
from at least 16 individuals in a control population for a set of
genomic loci; b) determining case genotypes, wherein said case
genotypes are genotypes from individuals that react in an altered
manner to administration of a substance for said set of genomic
loci; and c) comparing frequencies of said control genotypes with
frequencies of said case genotypes, wherein members of said set of
genomic loci that exhibit differences in said frequencies indicate
locations of pharmacogenomic-related genetic loci.
24. The method of claim 25, further comprising using said
pharmacogenomic-related genetic loci for a purpose selected from
the group consisting of: testing of a candidate agent;
stratification of a population for clinical studies; development of
a gene therapy; and use as a drug discovery target.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application claims priority to and is a
continuation-in-part of U.S. provisional patent application Ser.
No. 60/280,530, filed Mar. 30, 2001; U.S. provisional patent
application Ser. No. 60/313,264 filed Aug. 17, 2001; U.S.
provisional patent application Ser. No. 60/327,006, filed Oct. 5,
2001, all entitled "Identifying Human SNP Haplotypes, Informative
SNPs and Uses Thereof"; and U.S. provisional patent application
Ser. No. 60/332,550, filed Nov. 26, 2001, entitled "Methods for
Genomic Analysis"; and the present application also claims priority
to and is a continuation of U.S. utility patent application Ser.
No. 10/106,097, filed Mar. 26, 2002, entitled "Methods for Genomic
Analysis", the disclosures of all of which are specifically
incorporated herein by reference in their entireties for all
purposes.
BACKGROUND OF THE INVENTION
[0002] The DNA that makes up human chromosomes provides the
instructions that direct the production of all proteins in the
body. These proteins carry out the vital functions of life.
Variations in the sequence of DNA encoding a protein produce
variations or mutations in the proteins encoded, thus affecting the
normal function of cells. Although environment often plays a
significant role in disease, variations or mutations in the DNA of
an individual are directly related to almost all human diseases,
including infectious disease, cancer, and autoimmune disorders.
Moreover, knowledge of genetics, particularly human genetics, has
led to the realization that many diseases result from either
complex interactions of several genes or their products or from any
number of mutations within one gene. For example, Type I and II
diabetes have been linked to multiple genes, each with its own
pattern of mutations. In contrast, cystic fibrosis can be caused by
any one of over 300 different mutations in a single gene.
[0003] Additionally, knowledge of human genetics has led to a
limited understanding of variations between individuals when it
comes to drug response--the field of pharmocogenetics. Over half a
century ago, adverse drug responses were correlated with amino acid
variations in two drug-metabolizing enzymes, plasma cholinesterase
and glucose-6-phosphate dehydrogenase. Since then, careful genetic
analyses have linked sequence polymorphisms (variations) in over 35
drug metabolism enzymes, 25 drug targets and 5 drug transporters
with compromised levels of drug efficacy or safety (Evans and
Relling, Science 296:487-91 (1999)). In the clinic, such
information is being used to prevent drug toxicity; for example,
patients are screened routinely for genetic differences in the
thiopurine methyltransferase gene that cause decreased metabolism
of 6-mercaptopurine or azathiopurine. Yet only a small percentage
of observed drug toxicities have been explained adequately by the
set of pharmacogenetic markers validated to date. Even more common
than toxicity issues may be cases where drugs demonstrated to be
safe and/or efficacious for some individuals have been found to
have either insufficient therapeutic efficacy or unanticipated side
effects in other individuals.
[0004] In addition to the importance of understanding the effects
of variations in the genetic make up of humans, understanding the
effects of variation in the genetic makeup of other non-human
organisms--particularly pathogens--is important in understanding
their effect on or interaction with humans. For example, the
expression of virulence factors by pathogenic bacteria or viruses
greatly affects the rate and severity of infection in humans that
come into contact with such organisms. In addition, a detailed
understanding of the genetic makeup of experimental animals, i.e.,
mice, rats, etc., is also of great value. For example,
understanding the variations in the genetic makeup of animals used
as model systems for evaluation of therapeutics is important for
understanding the test results obtained using these systems and
their predictive value for human use.
[0005] Because any two humans are 99.9% similar in their genetic
makeup, most of the sequence of the DNA of their genomes is
identical. However, there are variations in DNA sequence between
individuals. For example, there are deletions of many-base
stretches of DNA, insertion of stretches of DNA, variations in the
number of repetitive DNA elements in non-coding regions, and
changes in single nitrogenous base positions in the genome called
"single nucleotide polymorphisms" (SNPs). Human DNA sequence
variation accounts for a large fraction of observed differences
between individuals, including susceptibility to disease.
[0006] Although most SNPs are rare, it has been estimated that
there are 5.3 million common SNPs, each with a frequency of 10-50%,
that account for the bulk of the DNA sequence difference between
humans. Such SNPs are present in the human genome once every 600
base pairs (Kruglyak and Nickerson, Nature Genet. 27:235 (2001)).
Alleles (variants) making up blocks of such SNPs in close physical
proximity are often correlated, resulting in reduced genetic
variability and defining a limited number of "SNP haplotypes", each
of which reflects descent from a single, ancient ancestral
chromosome (Fullerton, et al., Am. J. Hum. Genet. 67:881
(2000)).
[0007] The complexity of local haplotype structure in the human
genome--and the distance over which individual haplotypes
extend--is poorly defined. Empiric studies investigating different
segments of the human genome in different populations have revealed
tremendous variability in local haplotype structure. These studies
indicate that the relative contributions of mutation,
recombination, selection, population history, and stochastic events
to haplotype structure vary in an unpredictable manner, resulting
in some haplotypes that extend for only a few kilobases (kb), and
others that extend for greater than 100 kb (A. G. Clark et al., Am.
J. Hum. Genet. 63:595 (1998)).
[0008] These findings suggest that any comprehensive description of
the haplotype structure of the human genome, defined by common
SNPs, will require empirical analysis of a dense set of SNPs in
many independent copies of the human genome. Such whole-genome
analyses would provide a fine degree of genetic mapping and
pinpoint specific regions of linkage. Until the present invention,
however, the practice and cost of genotyping over 3,000,000 SNPs
across each individual of a reasonably sized population has made
this endeavor impractical. The present invention allows for, among
a wide variety of applications, whole-genome association analysis
of populations using SNP haplotypes.
SUMMARY OF THE INVENTION
[0009] The present invention relates to methods for identifying
variations that occur in the human genome and relating these
variations to the genetic bases of phenotype such as disease
resistance, disease susceptibility or drug response. "Disease"
includes but is not limited to any condition, trait or
characteristic of an organism that it is desirable to change. For
example, the condition may be physical, physiological or
psychological and may be symptomatic or asymptomatic. The methods
allow for identification of variants, identification of SNPs,
determination of SNP haplotype blocks, determining SNP haplotype
patterns, and further, identification of informative SNPs for each
pattern, which affords genetic data compression.
[0010] Thus, one aspect of the present invention provides methods
for selecting SNP haplotype patterns useful in data analysis. Such
selection can be accomplished by isolating substantially identical
(homologous) nucleic acid strands from a plurality of individuals;
determining SNP locations in each nucleic acid strand; identifying
the SNP locations in the nucleic acid strands that are linked,
where the linked SNP locations form a SNP haplotype block;
identifying isolate SNP haplotype blocks; identifying SNP haplotype
patterns that occur in each SNP haplotype block; and selecting the
identified SNP haplotype patterns that occur in at least two of the
substantially identical nucleic acid strands. In one preferred
embodiment, nucleic acid strands from at least about 10 different
individuals or origins are used. In a more preferred embodiment,
nucleic acid strands from at least 16 different origins are used.
In an even more preferred embodiment, nucleic acid strands from at
least 25 different origins are used, and in a yet more preferred
embodiment, nucleic acid strands from at least 50 different origins
are used. Further, a more preferred embodiment would determine SNP
locations in at least about 100 nucleic acid strands from different
origins. In addition, this method may further comprise selecting
the SNP haplotype pattern that occurs most frequently in the
substantially identical nucleic acid strands; selecting the SNP
haplotype pattern that occurs next most frequently in the
substantially identical nucleic acid strands; and repeating the
selecting until the selected SNP haplotype patterns identify a
portion of interest of the substantially identical nucleic acid
strands. In a preferred embodiment, the portion of interest is
between 70% and 99% of the substantially identical nucleic acid
strands, and, in a more preferred embodiment, the portion of
interest is about 80% of the substantially identical nucleic acid
strands. Alternatively, one may wish to limit the selection of SNP
haplotype patterns to no more than about three SNP haplotype
patterns per SNP haplotype block.
[0011] In addition, the present invention provides a method for
selecting a data set of SNP haplotype blocks for data analysis,
comprising comparing SNP haplotype blocks for informativeness;
selecting a first SNP haplotype block with high informativeness;
adding the first SNP haplotype block to the data set; selecting a
second SNP haplotype block with high informativeness; adding the
second selected SNP haplotype block to the data set; and repeating
the selecting and adding steps until the region of interest of a
DNA strand is covered. In preferred embodiments, the SNP haplotype
blocks selected are non-overlapping.
[0012] The present invention further provides methods for
determining at least one informative SNP in a SNP haplotype
pattern, comprising first determining SNP haplotype patterns for a
SNP haplotype block, then comparing each SNP haplotype pattern of
interest in the SNP haplotype block to the other SNP haplotype
patterns of interest in the SNP haplotype block, and selecting at
least one SNP in each SNP haplotype pattern that distinguishes this
SNP haplotype pattern of interest from the other SNP haplotype
patterns of interest in the SNP haplotype block. The selected SNP
(or SNPs) is an informative SNP for the SNP haplotype pattern.
[0013] Also, the present invention allows for rapid scanning of
genomic regions and provides a method for determining
disease-related genetic loci or pharmacogenomic-related loci
without a priori knowledge of the sequence or location of the
disease-related genetic loci or pharmacogenomic-related loci. This
can be done by determining SNP haplotype patterns from individuals
in a control population, then determining SNP haplotype patterns
from individuals in a experimental population, such as individuals
in a diseased population or individuals that react in a particular
manner when administered a drug. The frequencies of the SNP
haplotype patterns of the control population are compared to the
frequencies of the SNP haplotype patterns of the experimental
population. Differences in these frequencies indicate locations of
disease-related genetic loci or pharmacogenomic-related loci.
[0014] An additional aspect of the present invention provides a
method of making associations between SNP haplotype patterns and a
phenotypic trait of interest comprising: building baseline of SNP
haplotype patterns of control individuals by the methods of the
present invention; pooling whole genomic DNA from a clinical
population having a common phenotypic trait of interest; and
identifying the SNP haplotype patterns that are associated with the
phenotypic trait of interest. Thus, the present invention allows
for genome scanning to identify multiple haplotype blocks
associated with a phenotype, which is particularly useful when
studying polygenic traits.
[0015] Also, the present invention provides a method for
identifying drug discovery targets comprising: associating SNP
haplotype patterns with a disease; identifying a chromosomal
location of the associated SNP haplotype patterns; determining the
nature of the association of the chromosomal location and said
disease; and using the gene or gene product of the chromosomal
location as a drug discovery target.
BRIEF DESCRIPTION OF THE FIGURES
[0016] The following figures and drawings form part of the present
specification and are included to further demonstrate certain
aspects of the patent invention. The invention may be better
understood by reference to one or more of these drawings in
combination with the detailed description of the specific
embodiments presented herein. FIG. 1 is a schematic of one
embodiment of the methods of the present invention from identifying
variant locations to associating variants with phenotype, to using
the associations to identify drug discovery targets or as
diagnostic markers.
[0017] FIG. 2 shows sample SNP haplotype blocks and SNP haplotype
patterns according to the present invention.
[0018] FIG. 3 is a schematic showing one embodiment of a method for
selecting SNP haplotype blocks.
[0019] FIG. 4 illustrates a simple employment of one embodiment of
the method shown in FIG. 3.
[0020] FIG. 5A is a schematic of one embodiment of a method for
choosing a final set up SNP haplotype blocks. FIG. 5B is a simple
employment of the method shown in FIG. 5A. The "letter:number"
designations in FIG. 5B indicate "haplotype block
ID:informativeness value" for each block.
[0021] FIG. 6 shows an example of how informative SNPs may be
selected according to one embodiment of the present invention.
[0022] FIG. 7A is a schematic showing one embodiment for resolving
variant ambiguities and/or SNP haplotype pattern ambiguities. FIG.
7B illustrates a simple employment of the method shown in FIG.
7A.
[0023] FIG. 8 is a schematic of one embodiment of using the methods
of the present invention in an association study.
[0024] FIG. 9 shows an exemplary computer network system suitable
for executing some embodiments of the present invention.
[0025] FIG. 10 is a schematic of the construction of somatic cell
hybrids.
[0026] FIG. 11 is a table illustrating a portion of results
obtained from screening hamster-human cell hybrids with the HuSNP
genechip from Affymetrix, Inc.
[0027] FIG. 12 shows an example of various amplified genomic
regions of human chromosome 22 and human chromosome 14 genomic DNA
using long range PCR.
[0028] FIG. 13A is a bar graph showing the percentage of SNPs
plotted against the frequency of the minor allele (variant) of the
SNP. FIG. 13B is a graph of the percentage of 200 kb intervals as a
function of the nucleotide diversity in the interval. FIG. 1 3C is
a bar graph showing the percentage of all intervals plotted against
interval length.
[0029] FIG. 14 shows the haplotype patterns for twenty independent
globally diverse chromosomes defined by 147 common human chromosome
21 SNPs.
[0030] FIG. 15 is a plot of the fraction of chromosome covered as a
function of the number of SNPs required for that coverage.
[0031] The present invention relates to methods for identifying
variations that occur in human genome and relating these variations
to the genetic basis of disease and drug response. In particular,
the present invention relates to identifying individual SNPs,
determining SNP haplotype blocks and patterns, and, further, using
the SNP haplotype blocks and patterns to dissect the genetic bases
of disease and drug response. The methods of the present invention
are useful in whole genome analysis.
DETAILED DESCRIPTION OF THE INVENTION
[0032] It readily should be apparent to one skilled in the art that
various embodiments and modifications may be made to the invention
disclosed in this application without departing from the scope and
spirit of the invention. All publications mentioned herein are
cited for the purpose of describing and disclosing reagents,
methodologies and concepts that may be used in connection with the
present invention. Nothing herein is to be construed as an
admission that these references are prior art in relation to the
inventions described herein.
[0033] As used in the specification, "a" or "an" means one or more.
As used in the claim(s), when used in conjunction with the word
"comprising", the words "a" or "an" mean one or more. As used
herein, "another" means at least a second or more.
[0034] As used herein, when the term "different origins" is used,
it refers to the fact DNA strands from different organisms come
from a different origin. Further, each DNA strand in a single
organism's genome come from different origins. In a diploid
organism, an individual organism's genome is made up of a set of
pairs of substantially identical DNA strands. That is, a single
individual would have substantially identical DNA strands from two
different origins--one DNA strand of the pair is of maternal origin
and one DNA strand of the pair is of paternal origin. Two or more
nucleic acid sequences--for example, two or more DNA strands--are
considered to be substantially identical if they exhibit at least
about 70% sequence identity at the nucleotide level, preferably
about 75%, more preferably about 80%, still more preferably about
85%, yet more preferably about 90%, even more preferably about 95%
and even more preferably nucleic acid sequences are considered to
be substantially identical if they exhibit at least about 98%
sequence identity at the nucleotide level. The extent of sequence
identity that is relevant between two or more nucleic acid
sequences will depend on the host source of the nucleic acids. For
example, a greater than 95% sequence identity may be relevant when
looking at same species comparisons, whereas a sequence identity of
70% or even less may be relevant when making cross species
comparisons. Of course, when one refers to DNA herein such
reference may include derivatives of DNA such as amplicons, RNA
transcripts, nucleic acid mimetics, etc.
[0035] As used herein, "individual" refers to a specific single
organism, such as a single animal, human insect, bacterium,
etc.
[0036] As used herein, "informativeness" of a SNP haplotype block
is defined as the degree to which a SNP haplotype block provides
information about genetic regions.
[0037] As used herein, the term "informative SNP" refers to a
genetic variant such as a SNP or subset (more than one) of SNPs
that tends to distinguish one SNP haplotype pattern from other SNP
haplotype patterns within a SNP haplotype block.
[0038] As used herein, the term "isolate SNP block" refers to a SNP
haplotype block that consists of one SNP.
[0039] As used herein, the term "linkage disequilibrium", "linked"
or "LD" refers to genetic loci that tend to be transmitted from
generation to generation together; e.g., genetic loci that are
inherited non-randomly.
[0040] As used herein, the term "singleton SNP haplotype" or
"singleton SNP" refers to a specific SNP allele or variant that
occurs in less than a certain portion of the population.
[0041] As used herein, the term "SNP" or "single nucleotide
polymorphism" refers to a genetic variation between individuals;
e.g., a single nitrogenous base position in the DNA of organisms
that is variable. As used herein, "SNPs" is the plural of SNP. Of
course, when one refers to DNA herein such reference may include
derivatives of DNA such as amplicons, RNA transcripts, etc.
[0042] As used herein, the term "SNP haplotype block" means a group
of variant or SNP locations that do not appear recombine
independently and that can be grouped together in blocks of
variants or SNPs.
[0043] As used herein, the term "SNP haplotype pattern" refers to
the set of genotypes for SNPs in a SNP haplotype block in a single
DNA strand.
[0044] As used herein, the term "SNP location" is the site in a DNA
sequence where a SNP occurs.
[0045] As used herein a "SNP haplotype sequence" is a DNA sequence
in a DNA strand that contains at least one SNP location.
[0046] Preparation of Nucleic Acids for Analysis
[0047] Nucleic acid molecules may be prepared for analysis using
any technique known to those skilled in the art. Preferably such
techniques result in the production of a nucleic acid molecule
sufficiently pure to determine the presence or absence of one or
more variations at one or more locations in the nucleic acid
molecule. Such techniques may be found, for example, in Sambrook,
et al., Molecular Cloning: A Laboratory Manual (Cold Spring Harbor
Laboratory, New York) (1989), and Ausubel, et al., Current
Protocols in Molecular Biology (John Wiley and Sons, New York)
(1997), incorporated herein by reference.
[0048] When the nucleic acid of interest is present in a cell, it
may be necessary to first prepare an extract of the cell and then
perform further steps--i.e., differential precipitation, column
chromatography, extraction with organic solvents and the like--in
order to obtain a sufficiently pure preparation of nucleic acid.
Extracts may be prepared using standard techniques in the art, for
example, by chemical or mechanical lysis of the cell. Extracts then
may be further treated, for example, by filtration and/or
centrifugation and/or with chaotropic salts such as guanidinium
isothiocyanate or urea or with organic solvents such as phenol
and/or HCCl.sub.3 to denature any contaminating and potentially
interfering proteins. When chaotropic salts are used, it may be
desirable to remove the salts from the nucleic acid-containing
sample. This can be accomplished using standard techniques in the
art such as precipitation, filtration, size exclusion
chromatography and the like.
[0049] In some instances, it may be desirable to extract and
separate messenger RNA from cells. Techniques and material for this
purpose are known to those skilled in the art and may involve the
use of oligo dT attached to a solid support such as a bead or
plastic surface. Suitable conditions and materials are known to
those skilled in the art and may be found in the Sambrook and
Ausubel references cited above. It may be desirable to reverse
transcribe the mRNA into cDNA using, for example, a reverse
transcriptase enzyme. Suitable enzymes are commercially available
from, for example, Invitrogen, Carlsbad CA. Optionally, cDNA
prepared from mRNA may then be amplified.
[0050] One approach particularly suitable for examining haplotype
patterns and blocks is using somatic cell genetics to separate
chromosomes from a diploid state to a haploid state. In one
embodiment, a human lymphoblastoid cell line that is diploid may be
fused to a hamster fibroblast cell line that is also diploid such
that the human chromosomes are introduced into the hamster cells to
produce cell hybrids. The resulting cell hybrids are examined to
determine which human chromosomes were transferred, and which, if
any, of the transferred human chromosomes are in a haploid state
(see, e.g., Patterson, et al., Annal. N.Y. Acad. Of Sciences,
396:69-81 (1982)).
[0051] A schematic of the procedure is shown in FIG. 10. FIG. 10
shows a diploid human lymphoblastoid cell line that is wildtype for
the thymidine kinase gene being fused to a diploid hamster
fibroblast cell line containing a mutation in the thymidine kinase
gene. In a sub-population of the resulting cells, human chromosomes
are present in hybrids. Selection for the human DNA-containing
hybrid cells is achieved by utilizing HAT medium (selective
medium). Only hybrid cells that have a stably-incorporated human
DNA strand having the wildtype human thymidine kinase gene grow in
cell culture medium containing HAT. Of the resulting hybrids, some
hybrids may contain both copies of some human chromosomes, only one
copy of a human chromosome or no copies of a particular human
chromosome. For example, for a human chromosome 22 having a locus
with either an A or a B allele, the resulting hybrid cells may
contain one human chromosome 22 variant (e.g., the "A" variant) or
a portion thereof, some may contain the other human chromosome 22
variant (the "B" variant) or a portion thereof, some may contain
both human chromosome 22 variants or portions thereof, and some
hybrids may not contain any portion of a human chromosome 22 at
all. In FIG. 10, only two of the resulting hybrid populations are
shown. Once the appropriate hybrids are selected, the nucleic acids
from these hybrids may be isolated by, for example, the techniques
described above and then subjected to SNP discovery, and haplotype
block and pattern analyses of the present invention.
[0052] Amplification Techniques
[0053] It may be desirable to amplify one or more nucleic acids of
interest before determining the presence or absence of one or more
variations in the nucleic acid. Nucleic acid amplification
increases the number of copies of the nucleic acid sequence of
interest. Any amplification technique known to those of skill in
the art may be used in conjunction with the present invention
including, but not limited to, polymerase chain reaction (PCR)
techniques. PCR may be carried out using materials and methods
known to those of skill in the art.
[0054] PCR amplification generally involves the use of one strand
of a nucleic acid sequence as a template for producing a large
number of complements to that sequence. The template may be
hybridized to a primer having a sequence complementary to a portion
of the template sequence and contacted with a suitable reaction
mixture including dNTPs and a polymerase enzyme. The primer is
elongated by the polymerase enzyme producing a nucleic acid
complementary to the original template.
[0055] For the amplification of both strands of a double stranded
nucleic acid molecule, two primers may be used, each of which may
have a sequence which is complementary to a portion of one of the
nucleic acid strands. Elongation of the primers with a polymerase
enzyme results in the production of two double-stranded nucleic
acid molecules each of which contains a template strand and a newly
synthesized complementary strand. The sequences of the primers
typically are chosen such that extension of each of the primers
results in elongation toward the site in the nucleic acid molecule
where the other primer hybridizes.
[0056] The strands of the nucleic acid molecules are denatured--for
example, by heating--and the process is repeated, this time with
the newly synthesized strands of the preceding step serving as
templates in the subsequent steps. A PCR amplification protocol may
involve a few to many cycles of denaturation, hybridization and
elongation reactions to produce sufficient amounts of the desired
nucleic acid.
[0057] Although PCR methods typically employ heat to achieve strand
denaturation and allow subsequent hybridization of the primers, any
other means that results in making the nucleic acids available for
hybridization to the primers may be used. Such techniques include,
but are not limited to, physical, chemical, or enzymatic means, for
example, by inclusion of a helicase, (see Radding, Ann. Rev.
Genetics 16: 405-436 (1982)) or by electrochemical means (see PCT
Application Nos. WO 92/04470 and WO 95/25177).
[0058] Template-dependent extension of primers in PCR is catalyzed
by a polymerase enzyme in the presence of at least 4
deoxyribonucleotide triphosphates (typically selected from dATP,
dGTP, dCTP, dUTP and dTTP) in a reaction medium which comprises the
appropriate salts, metal cations, and pH buffering system. Suitable
polymerase enzymes are known to those of skill in the art and may
be cloned or isolated from natural sources and may be native or
mutated forms of the enzymes. So long as the enzymes retain the
ability to extend the primers, they may be used in the
amplification reactions of the present invention.
[0059] The nucleic acids used in the methods of the invention may
be labeled to facilitate detection in subsequent steps. Labeling
may be carried out during an amplification reaction by
incorporating one or more labeled nucleotide triphosphates and/or
one or more labeled primers into the amplified sequence. The
nucleic acids may be labeled following amplification, for example,
by covalent attachment of one or more detectable groups. Any
detectable group known to those skilled in the art may be used, for
example, fluorescent groups, ligands and/or radioactive groups. An
example of a suitable labeling technique is to incorporate
nucleotides containing labels into the nucleic acid of interest
using a terminal deoxynucleotidyl transferase (TdT) enzyme. For
example, a nucleotide--preferably a dideoxy nucleotide--containing
a label is incubated with the nucleic acid to be labeled and a
sufficient amount of TdT to incorporate the nucleotide. A preferred
nucleotide is a dideoxynucleotide--i.e., ddATP, ddGTP, ddCTP,
ddTTP, etc--having a biotin label attached.
[0060] Techniques to optimize the amplification of long sequences
may be used. Such techniques work well on genomic sequences. The
methods disclosed in pending US patent applications U.S. Ser. No.
60/317,311, filed Sep. 05, 2001; U.S. Ser. No. [unassigned],
attorney docket number 1011N-1, filed Jan. 09, 2002 entitled
"Algorithms for Selection of Primer Pairs"; and U.S. Ser. No.
[assigned], attorney docket number 1011N1D1, filed Jan. 09, 2002,
entitled "Methods for Amplification of Nucleic Acids" are
particularly suitable for amplifying genomic DNA for use in the
methods of the present invention.
[0061] Amplified sequences may be subjected to other post
amplification treatments either before or after labeling. For
example, in some cases, it may be desirable to fragment the
amplified sequence prior to hybridization with an oligonucleotide
array. Fragmentation of the nucleic acids generally may be carried
out by physical, chemical or enzymatic methods that are known in
the art. Suitable techniques include, but are not limited to,
subjecting the amplified nucleic acids to shear forces by forcing
the nucleic acid containing fluid sample through a narrow aperture
or digesting the PCR product with a nuclease enzyme. One example of
a suitable nuclease enzyme is Dnase I. After amplification, the PCR
product may be incubated in the presence of a nuclease for a period
of time designed to produce appropriately sized fragments. The
sizes of the fragments may be varied as desired, for example, by
increasing the amount of nuclease or duration of incubation to
produce smaller fragments or by decreasing the amount of nuclease
or period of incubation to produce larger fragments. Adjusting the
digestion conditions to produce fragments of the desired size is
within the capabilities of a person of ordinary skill in the art.
The fragments thus produced may be labeled as described above.
[0062] Methods for the Detection of SNPs (SNP Discovery)
[0063] Determination of the presence or absence of one or more
variations in a nucleic acid may be made using any technique known
to those of skill in the art. Any technique that permits the
accurate determination of a variation can be used. Preferred
techniques will permit rapid, accurate determination of multiple
variations with a minimum of sample handling required. Some
examples of suitable techniques are provided below.
[0064] Several methods for DNA sequencing are well known and
generally available in the art and may be used to determine the
location of SNPs in a genome. See, for example, Sambrook, et al.,
Molecular Cloning: A Laboratory Manual (Cold Spring Harbor
Laboratory, New York) (1989), and Ausubel, et al., Current
Protocols in Molecular Biology (John Wiley and Sons, New York)
(1997), incorporated herein by reference. Such methods may be used
to determine the sequence of the same genomic regions from
different DNA strands where the sequences are then compared and the
differences (variations between the strands) are noted. DNA
sequencing methods may employ such enzymes as the Klenow fragment
of DNA polymerase I, Sequenase (US Biochemical Corp, Cleveland,
Ohio.), Taq polymerase (Perkin Elmer), thermostable T7 polymerase
(Amersham, Chicago, Ill.), or combinations of polymerases and
proofreading exonucleases such as those found in the Elongase
Amplification System marketed by Gibco/BRL (Gaithersburg, Md.).
Preferably, the process is automated with machines such as the
Hamilton Micro Lab 2200 (Hamilton, Reno, Nev.), Peltier Thermal
Cycler (PTC200; MJ Research, Watertown, Mass.) and the ABI Catalyst
and 373 and 377 DNA Sequencers (Perkin Elmer, Wellesley,
Mass.).
[0065] In addition, capillary electrophoresis systems which are
commercially available may be used to perform variation or SNP
analysis. In particular, capillary sequencing may employ flowable
polymers for electrophoretic separation, four different fluorescent
dyes (one for each nucleotide) which are laser activated, and
detection of the emitted wavelengths by a charge coupled device
camera. Output/light intensity may be converted to electrical
signal using appropriate software (e.g. Genotyper and Sequence
Naviagator, Perkin Elmer, Wellesley, Mass.) and the entire process
from loading of samples to computer analysis and electronic data
display may be computer controlled. Again, this method may be used
to determine the sequence of the same genomic regions from
different DNA strands where the sequences are then compared and the
differences (variations between the strands) are noted.
[0066] Optionally, once a genomic sequence from one reference DNA
strand has been determined by sequencing, it is possible to use
hybridization techniques to determine variations in sequence
between the reference strand and other DNA strands. These
variations may be SNPs. An example of a suitable hybridization
technique involves the use of DNA chips (oligonucleotide arrays),
for example, those available from Affymetrix, Inc. Santa Clara,
Calif. For details on the use of DNA chips for the detection of,
for example, SNPs, see U.S. Pat. No. 6,300,063 issued to Lipshultz,
et al., and U.S. Pat. No. 5,837,832 to Chee, et al., HuSNP Mapping
Assay, reagent kit and user manual, Affymetrix Part No. 90094
(Affymetrix, Santa Clara, Calif.), all incorporated by reference
herein.
[0067] In preferred embodiments, more than 10,000 bases of a
reference sequence and the other DNA strands are scanned for
variants. In more preferred embodiments, more than 1.times.10.sup.6
bases of a reference sequence and the other DNA strands are scanned
for variants, even more preferably more than 2.times.10.sup.6 bases
of a reference sequence and the other DNA strands are scanned, even
more preferably 1.times.10.sup.7 bases are scanned, and more
preferably more than 1.times.10.sup.8 bases are scanned, and more
preferably more than 1.times.10.sup.9 bases of a reference sequence
and the other DNA strands are scanned for variants. In preferred
embodiments at least exons are scanned for variants, and in more
preferred embodiments both introns and exons are scanned for
variants. In an even more preferred embodiment, introns, exons and
intergenic sequences are scanned for variants. In preferred
embodiments the scanned nucleic acids are genomic DNA, including
both coding and noncoding regions. In most preferred embodiments,
such DNA is from a mammalian organism such as a human. In preferred
embodiments, more than 10% of the genomic DNA from the organism is
scanned, in more preferred embodiments more than 25% of the genomic
DNA from the organism is scanned, in more preferred embodiments,
more than 50% of the genomic DNA from the organism is scanned, and
in most preferred embodiments, more than 75% of the genomic DNA is
scanned. In some embodiments of the present invention, known
repetitive regions of the genome are not scanned, and do not count
toward the percentage of genomic DNA scanned. Such known repetitive
regions may include Single Interspersed Nuclear Elements (SINEs,
such as alu and MIR sequences), Long Interspersed Nuclear Elements
(LINEs, such as LINE1 and LINE2 sequences), Long Terminal Repeats
(LTRs such as MaLRs, Retrov and MER4 sequences), transposons, and
MER1 And MER2 sequences.
[0068] Briefly, in one embodiment, labeled nucleic acids in a
suitable solution are denatured--for example, by heating to
95.degree. C.--and the solution containing the denatured nucleic
acids is incubated with a DNA chip. After incubation, the solution
is removed, the chip may be washed with a suitable washing solution
to remove un-hybridized nucleic acids, and the presence of
hybridized nucleic acids on the chip is detected. The stringency of
the wash conditions may be adjusted as necessary to produce a
stable signal. Detecting the hybridized nucleic acids may be done
directly, for example, if the nucleic acids contain a fluorescent
reporter group, fluorescence may be directly detected. If the label
on the nucleic acids is not directly detectable, for example,
biotin, then a solution containing a detectable label, for example,
streptavidin coupled to phycoerythrin, may be added prior to
detection. Other reagents designed to enhance the signal level may
also be added prior to detection, for example, a biotinylated
antibody specific for streptavidin may be used in conjunction with
the biotin, streptavidin-phycoerythrin detection system. In some
embodiments, the oligonucleotide arrays used in the methods of the
present invention contain at least 1.times.10.sup.6 probes per
array. In a preferred embodiment, the oligonucleotide arrays used
in the methods of the present invention contain at least
10.times.10.sup.6 probes per array. In a more preferred embodiment,
the oligonucleotide arrays used in the methods of the present
invention contain at least 50.times.10.sup.6 probes per array.
[0069] Once variant locations have been determined (SNP discovery)
by using, for example, sequencing or microarray analysis, it is
necessary to genotype the SNPs of control and sample populations.
The hybridization methods just described work well for this
purpose, providing an accurate and rapid technique for detecting
and genotyping SNPs in multiple samples. In addition, a technique
suitable for the detection of SNPs in genomic DNA--without
amplification--is the Invader technology available from Third Wave
Technologies, Inc., Madison, Wis. Use of this technology to detect
SNPs may be found, e.g., in Hessner, et al., Clinical Chemistry
46(8):1051-56 (2000); Hall, et al., PNAS 97(15):8272-77 (2000);
Agarwal, et al., Diag. Molec. Path. 9(3):158-64 (2000); and
Cooksey, et al., Antimicrobial and Chemotherapy 44(5):1296-1301
(2000). In the Invader process, two short DNA probes hybridize to a
target nucleic acid to form a structure recognized by a nuclease
enzyme. For SNP analysis, two separate reactions are run--one for
each SNP variant. If one of the probes is complementary to the
sequence, the nuclease will cleave it to release a short DNA
fragment termed a "flap". The flap binds to a fluorescently-labeled
probe and forms another structure recognized by a nuclease enzyme.
When the enzyme cleaves the labeled probe, the probe emits a
detectable fluorescence signal thereby indicating which SNP variant
is present.
[0070] An alternative to Invader technology, rolling circle
amplification utilizes an oligonucleotide complementary to a
circular DNA template to produce an amplified signal (see, for
example, Lizardi, et al., Nature Genetics 19(3):225-32 (1998); and
Zhong, et al., PNAS 98(7):3940-45 (2001)). Extension of the
oligonucleotide results in the production of multiple copies of the
circular template in a long concatemer. Typically, detectable
labels are incorporated into the extended oligonucleotide during
the extension reaction. The extension reaction can be allowed to
proceed until a detectable amount of extension product is
synthesized.
[0071] In order to detect SNPs using rolling circle amplification,
three probes and two circular DNA templates may be used. The first
probe--the target specific probe--may be constructed to be
complementary to a target nucleic acid molecule such that the
5'-terminus of the probe hybridizes to the nucleotide immediately
adjacent 5' to the SNP site in the target nucleic acid. The site of
the SNP is not base paired to the first probe.
[0072] The other two probes--rolling circle probes--are constructed
to have two 3'-terminals. This can be accomplished in various ways,
for example, by introducing a 5'-5' linkage in the central portion
of the probes resulting in a reversal of polarity of the nucleotide
sequence at that point. One end of each of the probes has a
sequence that is complementary to a portion of a different circular
template molecule while the other end is complementary to a portion
of the target nucleic acid sequence. The
target-sequence-complementary terminal is constructed such that the
3'-most nucleotide aligns with the nucleotide at the SNP site. One
of the probes may contain a nucleotide complementary to the
nucleotide at the SNP site in the target nucleic acid while the
other contains a nucleotide that is not complementary. In the
instance where two or more variants of the SNP are present in the
population, probes may be constructed to have 3'-nucleotides
complementary to the variants to be detected.
[0073] The probes--both target specific and rolling circle--may be
hybridized to the target sequence and contacted with a ligase
enzyme. When the 3'-most nucleotide of the rolling circle probe
forms a base pair with the nucleotide at the SNP site, the two
probes--the target specific and the rolling circle--are efficiently
ligated together. When the 3'-most nucleotide of the rolling circle
probe is not capable of base pairing with the nucleotide at the SNP
site in the target, the probes are not ligated. The unligated probe
is washed away and the sample is contacted with the template
circles, polymerase and labeled nucleoside triphosphates.
[0074] Another technique suitable for the detection of SNPs makes
use of the 5'-exonuclease activity of a DNA polymerase to generate
a signal by digesting a probe molecule to release a fluorescently
labeled nucleotide. This assay is frequently referred to as a
Taqman assay (see, e.g., Arnold, et al., BioTechniques 25(1):98-106
(1998); and Becker, et al., Hum. Gene Ther. 10:2559-66 (1999)). A
target DNA containing a SNP is amplified in the presence of a probe
molecule that hybridizes to the SNP site. The probe molecule
contains both a fluorescent reporter-labeled nucleotide at the
5'-end and a quencher-labeled nucleotide at the 3'-end. The probe
sequence is selected so that the nucleotide in the probe that
aligns with the SNP site in the target DNA is as near as possible
to the center of the probe to maximize the difference in melting
temperature between the correct match probe and the mismatch probe.
As the PCR reaction is conducted, the correct match probe
hybridizes to the SNP site in the target DNA and is digested by the
Taq polymerase used in the PCR assay. This digestion results in
physically separating the fluorescent labeled nucleotide from the
quencher with a concomitant increase in fluorescence. The mismatch
probe does not remain hybridized during the elongation portion of
the PCR reaction and is, therefore, not digested and the
fluorescently labeled nucleotide remains quenched.
[0075] Denaturing HPLC using a polystyrene-divinylbenzene reverse
phase column and an ion-pairing mobile phase can be used to
identify SNPs. A DNA segment containing a SNP is PCR amplified.
After amplification, the PCR product is denatured by heating and
mixed with a second denatured PCR product with a known nucleotide
at the SNP position. The PCR products are annealed and are analyzed
by HPLC at elevated temperature. The temperature is chosen to
denature duplex molecules that are mismatched at the SNP location
but not to denature those that are perfect matches. Under these
conditions, heteroduplex molecules typically elute before
homoduplex molecules. For an example of the use of this technique
see Kota, et al., Genome 44(4):523-28 (2001).
[0076] SNPs can be detected using solid phase amplification and
microsequencing of the amplification product. Beads to which
primers have been covalently attached are used to carry out
amplification reactions. The primers are designed to include a
recognition site for a Type II restriction enzyme. After
amplification--which results in a PCR product attached to the
bead--the product is digested with the restriction enzyme. Cleavage
of the product with the restriction enzyme results in the
production of a single stranded portion including the SNP site and
a 3'-OH that can be extended to fill in the single stranded
portion. Inclusion of ddNTPs in an extension reaction allows direct
sequencing of the product. For an example of the use of this
technique to identify SNPs see Shapero, et al., Genome Research
11(1 1):1926-34 (2001).
[0077] Data Analysis
[0078] FIG. 1 is a schematic showing the steps of one embodiment of
the methods of the present invention. Once SNPs (variants) have
been located or discovered by, e.g., the methods described supra
(step 110 of FIG. 1), SNP haplotype blocks, SNP haplotype patterns
within each SNP haplotype block, and informative SNPs for the SNP
haplotype patterns may be determined. One may use all SNPs or
variants located; alternatively, one may focus the analysis on only
a portion of the SNPs located. For example, the set of SNPs
analyzed may exclude transition SNPs of the form CgTg or cGcA. In
addition, in one embodiment of the present invention, the focus is
on common SNPs. Common SNPs are those SNPs whose less common form
is present at a minimum frequency in a given population. For
example, common SNPs are those SNPs that are found in at least
about 2% to 25% of the population. In a preferred embodiment,
common SNPs are those SNPs that are found in at least about 5% to
15% of the population. In a more preferred embodiment, common SNPs
are those that are found in at least about 10% of the population.
Common SNPs likely result from mutations that occurred early in the
evolution of humans. Focusing on common SNPs minimizes systematic
allele or variant differences between control and experimental
populations that appear as disease or drug-response associated, yet
result only from migratory history or mating practices; i.e.,
focusing on common SNPs decreases the false positives that result
from recent population anomalies. Moreover, common SNPs are
relevant to a larger proportion of the human population, making the
present invention more broadly applicable to disease and drug
response studies. Along the same line, SNPs in which an variant is
observed only once may be eliminated from analysis in some
embodiments of the present invention (for example, singleton SNPs).
However, certain analyses may be performed including some or all of
these singleton SNPs, particularly when looking at specific
sub-populations or populations that have been influenced by
migratory practices and the like.
[0079] In step 120 of FIG. 1, the variants or SNPs of interest are
assigned to haplotype blocks for evaluation. Variants or SNPs from
a whole genome or chromosome may be analyzed and assigned to SNP
haplotype blocks. Alternatively, variants from only a focused
genomic region specific to some disease or drug response mechanism
may be assigned to the SNP haplotype blocks.
[0080] FIG. 2 provides one illustration of showing how variants,
usually SNPs, occur in haplotype blocks in a genome, and that more
than one haplotype pattern can occur within each haplotype block.
If SNP haplotype patterns were completely random, it would be
expected that the number of possible SNP haplotype patterns
observed for a SNP haplotype block of N SNPs would be 2.sup.N.
However, it was observed in performing the methods of the present
invention that the number of SNP haplotype patterns in each SNP
haplotype block is smaller than 2.sup.N because the SNPs are linked
(not 4.sup.N, as the variants will most commonly be biallelic,
i.e., occur in only one of two forms, not all four nucleotide base
possibilities). Certain SNP haplotype patterns were observed at a
much higher frequency than would be expected in a non-linkage case.
Thus, SNP haplotype blocks are chromosomal regions that tend to be
inherited as a unit, with a relatively small number of common
patterns. Each line in FIG. 2 represents portions of the haploid
genome sequence of different individuals. As shown therein,
individual W has an "A" at position 241, a "G" at position 242, and
an "A" at position 243. Individual X has the same bases at
positions 241, 242, and 243. Conversely, individual Y has a T at
positions 241 and 243, but an A at position 242. Individual Z has
the same bases as individual Y at positions 241, 242, and 243.
Variants in block 261 will tend to occur together. Similarly, the
variants in block 262 will tend to occur together, as will those
variants in block 263. Of course, only a few bases in a genome are
shown in FIG. 2. In fact, most bases will be like those at position
245 and 248, and will not vary from individual to individual.
[0081] The assignment of SNPs to SNP haplotype blocks, step 120 of
FIG. 1, is, in one case, an iterative process involving the
construction of SNP haplotype blocks from the SNP locations along a
genomic region of interest. In one embodiment, once the initial SNP
haplotype blocks are constructed, SNP haplotype patterns present in
the constructed SNP haplotype blocks are determined (step 130 of
FIG. 1). In some specific embodiments, the number of SNP haplotype
patterns selected per SNP haplotype block in step 130 is no greater
than about five. In another specific embodiment, the number of SNP
haplotype patterns selected per SNP haplotype block is equal to the
number of SNP haplotype patterns necessary to identify SNP
haplotype patterns in greater than 50% of the DNA strands being
analyzed. In other words, enough SNP haplotype patterns are
selected, for example, four patterns per block are selected, such
that at least half of the DNA strands analyzed will have a SNP
haplotype pattern that matches one of the four patterns selected in
each SNP haplotype block. In a preferred embodiment, the number of
SNP haplotype patterns selected per SNP haplotype block is equal to
the number of SNP haplotype patterns necessary to identify SNP
haplotype patterns in greater than 70% of the DNA strands being
analyzed. In one preferred embodiment, the number of SNP haplotype
patterns selected per SNP haplotype block is equal to the number of
SNP haplotype patterns necessary to identify SNP haplotype patterns
in greater than 80% of the DNA strands being analyzed. In addition,
in some embodiments of the present invention, SNP haplotype
patterns that occur in less than a certain portion of DNA strands
being analyzed are eliminated from analysis. For example, in one
embodiment, if ten DNA strands are being analyzed, SNP haplotype
patterns that are found to occur in only one sample out of ten are
eliminated from analysis.
[0082] Once the SNP haplotype patterns of interest are selected,
informative SNPs for these SNP haplotype patterns are determined
(step 140 of FIG. 1). From this initial set of blocks, a set of
candidate SNP blocks that fit certain criteria for informativeness
is constructed (step 150 of FIG. 1). FIGS. 4 and 5 illustrate steps
120, 130, 140 and 150 in more detail.
[0083] In FIG. 3, step 310 provides that a new block of SNPs is
chosen for evaluation. In one embodiment, the first block chosen
contains only the first SNP in a SNP haplotype sequence; thus at
step 320, the first, single, SNP is added to the block. At step
330, informativeness of this block is determined.
[0084] "Informativeness" of a SNP haplotype block is defined in one
embodiment as the degree to which the block provides information
about genetic regions. For example, in one embodiment of the
present invention, informativeness could be calculated as the ratio
of the number of SNP locations in a SNP haplotype block divided by
the number of SNPs required to distinguish each SNP haplotype
pattern under consideration from other SNP haplotype patterns under
consideration (number of informative SNPs) in that block. Another
measure of informativeness might be the number of informative SNPs
in the block. One skilled in the art recognizes that
informativeness may be determined in any number of ways.
[0085] Referring again to FIG. 2, SNP haplotype block 261 contains
three SNPs and two SNP haplotype patterns (AGA and TAT). Any one of
the three SNPs present can be used to tell the patterns apart;
thus, any one of these SNPs can be chosen to be the informative SNP
for this SNP haplotype pattern. For example, if it is determined
that a sample nucleic acid contains a T at the first position, the
same sample will contain an A at the second position and a T at the
third position. If it is determined in a second sample that the SNP
in the second position is a G, the first and third SNPs will be
A's. Thus, by one measure of informativeness, the informativeness
value for this first block is 3:3 total SNPs divided by 1
informative SNP needed to distinguish the patterns from each other.
Similarly, SNP haplotype block 262 contains three SNPs (two
positions do not have variants) and two haplotype patterns (TCG and
CAC). As with the previously-analyzed block, any one of the three
SNPs can be evaluated to tell one pattern from the other; thus, the
informativeness of this block is 3:3 total SNPs divided by 1
informative SNP needed to distinguish the patterns. SNP haplotype
block 263 contains five SNPs and two SNP patterns (TAACG and
ATCAC). Again, any one of the five SNPs can be used to tell one
pattern from the other; thus, the informativeness of this block is
5:5 total SNPs divided by 1 informative SNP needed to distinguish
the patterns.
[0086] FIG. 2 provides a simple example of genetic analysis. When
several SNP haplotype patterns are present in a block, it may be
necessary to use more than one SNP as informative SNPs. For
example, in a case where a block contains, for example, six SNPs
and two SNPs are needed to distinguish the patterns of interest,
the informativeness of the block is 3:6 total SNPs divided by 2
SNPs needed to distinguish the patterns. Generally speaking, as
many as 2.sup.N distinct SNP haplotype patterns can be
distinguished by using the genotypes of N suitably selected SNPs.
Therefore, if there exist only two SNP haplotype patterns in the
SNP haplotype block, a single SNP should be able to differentiate
between the two. If there are three or four patterns, at least two
SNPs would likely be required, etc.
[0087] In step 340 of FIG. 3, once the informativeness of a SNP
haplotype block is determined, a test is performed. The test
essentially evaluates the SNP haplotype blocks based on selected
criteria (for example, whether a block meets a threshold measure of
informativeness), and the result of the test determines whether,
for example, another SNP will be added to the block for analysis or
whether the analysis will proceed with a new block starting at a
different SNP location. FIG. 4 illustrates one embodiment of this
process.
[0088] In FIG. 4, assume there is a DNA sequence with six SNP
locations. The analysis of SNP haplotype blocks described above
might be performed in the following manner: SNP haplotype block A
is selected containing only the SNP at SNP position 1 (steps 310
and 320 of FIG. 3). The informativeness of this block is calculated
(step 330), and it is determined whether the informativeness of
this block meets a threshold measure of informativeness (step 340).
In this case, it "passes" and two things happen. First, this block
of one SNP (SNP position 1) is added to the set of candidate SNP
haplotype blocks (step 350). Second, another SNP (here, SNP
position 2) is added to this block (step 320) to create a new
block, B, containing SNP positions 1 and 2, which is then analyzed.
In this illustration block B also meets the threshold measure of
informativeness (step 340), so it would be added to the set of
candidate SNP haplotype blocks (step 350), and another SNP (here,
SNP position 3) is added to this block (step 320) to create new
block C, containing SNP positions 1, 2 and 3, which is then
analyzed. In this illustration, C also meets the threshold measure
of informativeness and it is added to the set of candidate SNP
haplotype blocks (step 350), and another SNP (here, SNP position 4)
is added to this block (step 320) to create new block D, containing
SNP positions 1, 2, 3, and 4, which is then analyzed. In the FIG. 4
illustration, SNP block D does not meet the threshold measure of
informativeness. SNP block D is not added to the set of candidate
SNP haplotype blocks (step 350), nor does another SNP get added to
block D for analysis. Instead, a new SNP location is selected for a
round of SNP block evaluations.
[0089] In FIG. 4, after block D fails to meet the threshold measure
of informativeness, a new block, E, is selected that contains only
the SNP at position 2. Block E is evaluated for informativeness, is
found to meet the threshold measure, is added to the set of
candidate SNP haplotype blocks (step 350), and another SNP (here,
SNP position 3) is added to this block (step 320) to create new
block F, containing SNP positions 2 and 3, which is then analyzed,
and so on. Note that block H fails to meet the threshold measure of
informativeness, is not added to the set of candidate SNP haplotype
blocks (step 350), nor does another SNP get added to block H for
analysis. Instead, a new block, I, is selected that contains only
the SNP at position 3, and so on.
[0090] Once a set of candidate SNP blocks is constructed (step 350
of FIG. 3), analysis is performed on the set to select a final set
of SNP blocks (step 160 of FIG. 1). The selection of the final set
of SNP blocks can performed in a variety of ways. For example,
referring back to FIG. 4, one could select the largest block
containing SNP position 1 that passes the threshold test (block C,
containing SNPs 1, 2 and 3), discard the smaller blocks that
contain the same SNPs (blocks A and B). Then the next block
selected might be the next block starting with SNP position 4 that
is the largest block that meets the threshold test for
informativeness (block G) and the smaller blocks that contain the
same SNPs (blocks E and F) would be discarded. Such a method would
give a set of final, non-overlapping SNP haplotype blocks that span
the genomic region of interest, contain the SNPs of interest and
that have a high level of informativeness. Thus, once all candidate
SNP haplotype blocks are evaluated, the result may be, in a
preferred embodiment, a set of non-overlapping SNP haplotype blocks
that encompasses all the SNPs in the original set. Some groups,
called isolates, may consist of only a single SNP, and by
definition have an informativeness of 1. Other groups may consist
of a hundred or more SNPs, and have an informativeness exceeding
30.
[0091] An alternative method for selecting a final set of SNP
haplotype blocks is shown in FIGS. 5A and 5B. Looking first at FIG.
5A, in a first step 510, the candidate SNP haplotype block set
(generated, for example, by the methods described in FIGS. 3 and 4
herein) is analyzed for informativeness. In step 520, the candidate
SNP haplotype block with the highest informativeness in the entire
candidate set is chosen to be added to the final SNP haplotype
block set (step 530). Once this candidate SNP haplotype block is
chosen to be a member of the final SNP haplotype block set, it is
deleted from the candidate block set (step 540), and all other
candidate SNP haplotype blocks that overlap with the chosen block
are deleted from the candidate SNP haplotype block set (step 550).
Next, the candidate SNP haplotype blocks remaining in the candidate
set are analyzed for informativeness (step 510), and the candidate
SNP haplotype block with the highest informativeness is chosen to
be added to the final SNP haplotype block set (steps 520 and 530).
As before, once this SNP haplotype block is chosen to be a member
of the final SNP haplotype block set, it is deleted from the
candidate block set (step 540), and all other candidate SNP
haplotype blocks that overlap with the chosen block are deleted
from the candidate SNP haplotype block set (step 550). The process
continues until a final set of non-overlapping SNP haplotype blocks
that encompasses all the SNPs in the original set is
constructed.
[0092] FIG. 5B illustrates a simple employment of the method of
selecting a final set of SNP haplotype blocks described in FIG. 5A.
In FIG. 5B, a sequence 5' to 3' is analyzed for SNPs, SNP haplotype
patterns and candidate SNP haplotype blocks according to the
methods of the present invention. Candidate SNP haplotype blocks
contained within this sequence are indicated by their placement
under the sequence, and are designated by a letter. In addition,
after the letter, the informativeness of each block is indicated.
For example, candidate SNP haplotype block A is located at the
extreme 5' end of the sequence, and has an informativeness of 1.
Candidate SNP haplotype block R is located at the extreme 3' end of
the sequence, and has an informativeness of 2.
[0093] According to FIG. 5A, in a first step 510, the candidate SNP
haplotype blocks are analyzed for informativeness, and in step 520,
the SNP haplotype block with the highest informativeness is chosen
to be added to the final SNP haplotype block set (steps 520 and
530). In the case of FIG. 5B, candidate SNP haplotype block M with
an informativeness of 6 would be the first candidate SNP haplotype
block selected to be added to the final SNP haplotype block set.
Once SNP haplotype block M is selected, it is deleted or removed
from the candidate set of SNP haplotype blocks (step 540), and all
other candidate SNP haplotype blocks that overlap with SNP
haplotype block M (blocks J, N, K, L, O and P) are deleted from the
candidate SNP haplotype block set (step 550). Next, the remaining
blocks of the candidate SNP haplotype block set, namely SNP
haplotype blocks A, B, C, D, E, F, G, H, I, Q and R are analyzed
for informativeness, and in step 520, the remaining SNP haplotype
block with the highest informativeness, I, with an informativeness
of 5, is chosen to be added to the final SNP haplotype block set
(530) and deleted or removed from the candidate set of SNP
haplotype blocks (step 540). Next, in step 550, all other candidate
SNP haplotype blocks that overlap with SNP haplotype block I, here,
only block H, is deleted from the candidate SNP haplotype block
set. Again, the remaining blocks of the candidate SNP haplotype
block set, namely SNP haplotype blocks A, B, C, D, E, F, G, Q and R
are analyzed for informativeness. In step 520, the remaining SNP
haplotype block with the highest informativeness, block F, with an
informativeness of 4, is chosen to be added to the final SNP
haplotype block set (530) and deleted or removed from the candidate
set of SNP haplotype blocks (step 540). Next, all other candidate
SNP haplotype blocks that overlap with SNP haplotype block F--here,
blocks E, G, C and D--are deleted from the candidate SNP haplotype
block set, and the remaining blocks of the candidate SNP haplotype
block set, namely SNP haplotype blocks A, B, Q and R, are analyzed
for informativeness, and so on.
[0094] Other methods can be employed to select a final set of SNP
haplotype blocks for analysis from the set of candidate SNP
haplotype blocks (step 160 of FIG. 1). For example, algorithms
known in the art may be applied for this purpose. For example,
shortest-paths algorithms may be used (see, generally, Cormen,
Leiserson, and Rivest, Introduction to Algorithms (MIT Press) pp.
514-78 (1994). In a shortest-paths problem, a weighted, directed
graph G=(V,E), with weight function w:E.fwdarw.R mapping edges to
real-valued weights is given. The weight of path p=(v.sub.0,
v.sub.1, . . . v.sub.k) is the sum of the weights of its
constituent edges: 1 w ( p ) = i = 1 k w ( v i - 1 , v i ) .
[0095] The shortest-path weight from u to v is defined by
.delta.(u,v) being equal to min w(p):u.fwdarw.v if there is a path
from u to v; otherwise, .delta.(u,v) is equal to infinity. A
shortest path from vertex u to vertex v is then defined as any path
p with weight w(p)=.delta.(u,v). Edge weights can be interpreted as
various metrics: for example, distance, time, cost, penalties,
loss, or any other quantity that accumulates linearly along a path
that one wishes to minimize. In the embodiment of the shortest path
algorithm used in applications of this invention, each SNP
haplotype block would be considered a "vertex" with an "edge"
defined for each boundary of the block. Each SNP haplotype block
has a relationship to each other SNP haplotype block, with a "cost"
for each edge. Cost is determined by parameters of choice, such as
overlap (or the extent thereof) of the vertices or gaps between the
vertices.
[0096] Single-source shortest-paths problems focus on a given graph
G=(V,E), where a shortest path from a given source vertex s
.epsilon. V to every vertex v .epsilon. V is determined.
Additionally, variants of the single source algorithm may be
applied. For example, one may apply a single-destination
shortest-paths solution where a shortest path to a given
destination vertex t from every vertex v is found. Reversing the
direction of each edge in the graph reduces this problem to a
single-source problem. Alternatively, one may apply a single-pair
shortest-path problem where the shortest path from u to v for given
vertices u and v is found. If the single-source problem with source
vertex u is solved, the single-source shortest path problem is
solved as well. Also, the all-pairs shortest-paths approach may be
employed. In this case, a shortest path from u to v for every pair
of vertices u and v is found--a single-source algorithm is run from
each vertex.
[0097] One single-source shortest-path algorithm that may be
employed in the methods of the present invention is Dijkstra's
algorithm. Dijkstra's algorithm solves the single-source
shortest-paths problem on a weighted, directed graph G=(V, E) for
the case in which all edge weights are nonnegative. Dijkstra's
algorithm maintains a set of vertices, S, whose final shortest-path
weights from a source s have already been determined. That is, for
all vertices v being elements of S, d[v]=.delta.(s,v). The
algorithm repeatedly selects the vertex u as an element of V-S with
the minimum shortest-path estimate, inserts u into S, and relaxes
all edges radiating from u. In one implementation, a priority queue
Q that contains all the vertices in V-S, keyed by their d values,
is maintained. This implementation assumes that graph G is
represented by adjacency lists.
[0098] Dijkstra (G, w, s)
[0099] 1 Initialize-Single Source (G,s)
[0100] 2 S.rarw..o slashed.
[0101] 3 Q.rarw.V[G]
[0102] 4 while Q.noteq..o slashed.
[0103] 5 do u.rarw.Extract-Min (Q)
[0104] 6 S.rarw.S U {u}
[0105] 7 for each vertex v .epsilon. Adj[u]
[0106] 8 do RELAX (u,v,w)
[0107] G in this case is the graph of linear coverage of the
genomic sequence being analyzed is the set of vertices selected.
Once one vertex is selected that covers a particular area genomic
sequence, other vertices that overlap this sequence can be
discarded.
[0108] Other algorithms that may be used for selecting SNP
haplotype blocks include a greedy algorithm (again, see, Cormen,
Leiserson, and Rivest, Introduction to Algorithms (MIT Press) pp.
329-55 (1994)). A greedy algorithm obtains an optimal solution to a
problem by making a sequence of choices. For each decision point in
the algorithm, the choice that seems best at the moment is chosen.
This heuristic strategy does not always produce an optimal
solution. Greedy algorithms differ from dynamic programming in that
in dynamic programming, a choice is made at each step, but the
choice may depend on the solutions to subproblems. In a greedy
algorithm, whatever choice seems best at the moment is chosen and
then subproblems arising after the choice is made are solve. Thus,
the choice made by a greedy algorithm may depend on the choices
made thus far, but cannot depend on any future choices or on the
solutions to subproblems. One variation of greedy algorithms is
Huffman codes. A Huffman greedy algorithm constructs an optimal
prefix code and the algorithm builds a tree T corresponding to the
optimal code in a bottom-up manner. It begins with a set of
.vertline.C.vertline. leaves and performs a sequence of
.vertline.C.vertline.-1 "merging" operations to create the final
tree. For example, assuming C is a set of n characters and that
each character c .epsilon. C is an object with a defined frequency
f[c]; a priority queue Q, keyed on f, is used to identify the two
least-frequent objects to merge together. The result of the merger
of two objects is a new object whose frequency is the sum of the
frequencies of the two objects that were merged. For example:
[0109] 1. n.rarw..vertline.C.vertline.
[0110] 2. Q.rarw.C
[0111] 3. for i.rarw.1 to n-1
[0112] 4. do z.rarw.Allocate-Node( )
[0113] 5. x.rarw.left[z].rarw.Extract-Min(Q)
[0114] 6. y.rarw.right[z].rarw.Extract-Min(Q)
[0115] 7. f[z].rarw.f[x]+j[y]
[0116] 8. Insert (Q,z)
[0117] 9. return Extract-Min(Q)
[0118] Line 2 initializes the priority queue Q with the characters
in C. The for loop in lines 3-8 repeatedly extracts the two nodes x
and y of lowest frequency from the queue, and replaces them in the
queue with a new node z representing their merger. The frequency of
z is computed as the sum of the frequencies of x and y in line 7.
The node z has x as its left child and y as its right child. After
n-1 mergers, the one node left in the queue--the root of the code
tree--is returned in line 9.
[0119] Again, these methods result in a set of final,
non-overlapping SNP haplotype blocks that encompasses all SNPs
evaluated in a particular genomic region. An important result of
selecting SNPs, SNP haplotype blocks and SNP haplotype patterns
according to the methods of the present invention, is that in some
embodiments during the calculation of informativeness of SNP
haplotype blocks, informative SNPs for each SNP haplotype block and
pattern are determined. Informative SNPs allow for data
compression.
[0120] In one embodiment of the present invention, the selection of
at least 10g.sub.2 p SNPs from each group containing p patterns
(rounding up to the nearest integer) provides one set of
informative SNPs which are unusually powerful for predicting
genotype/phenotype associations. One skilled in the art recognizes
that in other analyses it is not necessary to use spatially
contiguous groups to determine such a subset. For example, in some
embodiments of the present invention, it may be desirable to
identify sets of non-adjacent SNPs that statistically are passed on
in a fashion analogous to that of SNP haplotype blocks even though
they are not spatially contiguous on the DNA strand.
[0121] In order to determine SNP haplotype blocks that will be used
in association studies accurately (build an accurate baseline of
SNPs and SNP haplotype blocks and patterns), it is necessary to
examine more than a few individual DNA strands. FIG. 6 illustrates
the importance of examining at least about five different DNA
strands for determining SNP haplotype blocks and for the selection
of informative SNPs. The top portion of FIG. 6 illustrates the
sequence of a hypothetical stretch of DNA, with the variant
positions indicated and variant block boundaries drawn; however,
SNP haplotype block boundaries would not be known ab initio.
Sequencing results 610 show the results of sequencing haploid DNA
of three individuals. As shown, in general it is possible to have
identified a large fraction of the common SNPs after a relatively
small number of individuals have been sequenced. In the case in
FIG. 6, the SNPs at each location shown in the top portion of FIG.
6 have been identified, as indicated by check marks.
[0122] If, however, further individuals are not evaluated, the
block boundaries would not be correctly identified at this stage.
For example, while one could at this stage draw block boundaries
between blocks 620 and 630 (note that the first C.fwdarw.G variant
predicts the first G.fwdarw.A variant, and the first C.fwdarw.T
variant predicts the second C.fwdarw.T variant), it is not possible
to distinguish between the blocks 630 and 640 at this stage. At
this stage it appears that the first C.fwdarw.T variant would
predict the first and second T.fwdarw.A variants. Accordingly, a
more statistically significant sample set is required to draw the
block boundaries. For example, in the methods of the present
invention, the number of DNA strands analyzed to determine SNP
haplotype blocks, SNP haplotype patterns, and/or informative SNPs
is a plurality, for example, at least about five or at least about
10. In preferred embodiments, the number of DNA stands is at least
16. In more preferred embodiments, the number of DNA strands
analyzed to determine SNP haplotype blocks, SNP haplotype patterns,
and/or informative SNPs is at least 25. However, once relevant SNPs
have been identified (i.e., SNP discovery has been performed), it
is possible to genotype only the variant positions in the remaining
samples to complete the process of identifying block boundaries
without sequencing the entire stretch of genomic DNA. For examples
of such methods, see U.S. Ser. No. 10/042,819, filed Jan. 06, 2002,
attorney docket number 1016N-1, entitled "Whole Genome
Scanning".
[0123] The results of performing a genotyping process on only the
SNPs in another hypothetical genomic sample are shown in FIG. 6 at
650. As shown, by performing this additional genotyping step, it is
now possible to see that blocks 630 and 640 are distinguishable.
Specifically, it is now possible to see that the first C.fwdarw.T
variant does not track with the first and second T.fwdarw.A
variants, but instead, the first C.fwdarw.T variant can be used to
predict only the second C.fwdarw.T variant (and vice versa) and the
first T.fwdarw.A variant can be used only to predict the second
T.fwdarw.A variant (and vice versa).
[0124] In addition to the aspects of the present invention
described above, a specific embodiment of the present invention is
that it can be employed to resolve ambiguous SNP haplotype
sequences for data analysis. For example, a SNP may be ambiguous
because data from a gel sequencing operation or array hybridization
experiment does not give a clear result. "Resolving" in this case
may mean, e.g., resolving ambiguous SNP locations in a SNP
haplotype sequence by matching the SNP haplotype sequence to the
SNP haplotype pattern to which the SNP haplotype sequence most
closely relates. Additionally, "resolving" may mean removing an
ambiguous SNP haplotype sequence from data analysis.
[0125] In one embodiment of resolving ambiguous SNP haplotype
sequences, SNP haplotype sequences are placed in a data set for
possible addition to a pattern set. The data set will contain all
SNP haplotype sequences that are to be evaluated for possible
assignment to a SNP haplotype pattern. Referring now to FIG. 7A, in
step 710, the SNP haplotype sequences in the data set are compared,
one by one, to the pattern sequences in the pattern set. In some
cases, there will be no patterns in the pattern set initially,
though in other cases some or all pattern sequences may be known
beforehand. In step 720, a query is made: is the SNP haplotype
sequence from the data set consistent with a pattern sequence in
the pattern set? If the answer is no, step 730 provides the SNP
haplotype sequence being evaluated will be added to the pattern
set. If the answer is yes, another query is made (740): is the SNP
haplotype sequence from the data set consistent with more than one
pattern sequence in the pattern set?
[0126] If the answer is yes, the SNP sequence from the data set may
be discarded or, in some embodiments, held for further or different
analyses (step 750). If the answer to the second query is no, then,
in step 760, the SNP sequence from the data set is compared to the
pattern sequence from the pattern set with which it is consistent.
From these two sequences, the SNP sequence with the least number of
ambiguities is selected and placed in the pattern set (770). The
SNP sequence containing the more ambiguities may be discarded, or,
in some embodiments, held for further or different types of
analyses.
[0127] The resolving process may be understood further by referring
to FIGS. 7A and 7B. In FIG. 7B, a first SNP sequence, TTCGA, is
compared to the sequences contained in the pattern set (step 710).
At this point, there are no pattern sequences contained in the
pattern set, thus TTCGA is not consistent with any pattern sequence
in the pattern set. This occurrence of SNP sequence TTCGA is then
removed from the data set (or is retained for different analyses),
and added to the pattern set (730). The pattern set now has one
pattern sequence, TTCGA.
[0128] Looking again at FIG. 7B, the second SNP sequence in the
data set, T?C??, is compared to the sequence contained in the
pattern set (step 710). Now there is one pattern sequence in the
pattern set, TTCGA, and T?C?? is consistent with sequence (step
720). The answer to the second query (740), whether SNP sequence
T?C?? is consistent with more than one pattern sequence in the
pattern set, is no, as currently there is only one pattern
sequence, TTCGA, in the pattern set. In step 760, T?C?? is compared
to TTCGA to determine which sequence has the more ambiguities.
T?C?? clearly does; thus, TTCGA is retained in the pattern set
(770) and T?C?? may be discarded or held for further analyses.
[0129] The third sequence of the data set in FIG. 7B is C????.
C???? first is compared to TTCGA (step 710), is found not to be
consistent with TTCGA (720), and is thus added to the pattern set
(730). The fourth sequence in FIG. 7B is CTACA. CTACA is compared
to TTCGA and C???? (the pattern sequences in the pattern set, step
710), and is found to be consistent with C???? (720). The second
query (740) now is made: is CTACA consistent with both C???? and
TTCGA? The answer is no, so C???? and CTACA are then compared (760)
and the sequence with the least number of ambiguities, in this
case, CTACA, is held in the pattern set and C???? is discarded
(removed from analysis), or held for further analyses (770).
[0130] The fifth SNP sequence in the data set in FIG. 7B is ?T??A.
This SNP sequence is compared to pattern sequences TTCGA and CTACA
(710) and is found to be consistent with both TTCGA and CTACA.
Thus, the answer to query 740 is yes: ?T??A is consistent with more
than one pattern sequence in the pattern set. In step 750, SNP
sequence ?T??A is held for further analysis or discarded (removed
from analysis).
[0131] Another approach to resolving allows that if, for example,
one pattern sequence is CCATT? and a SNP sequence from the data set
is C?ATTG, the sequences are "combined" to solve the ambiguities
(CCATTG), and the "combined" sequence is added to the pattern set.
Additional array hybridizations, sequencing or other techniques
known in the art may be employed to analyze ambiguous SNP
nucleotide positions.
[0132] Association of Phenotypes with SNP Haplotypes Blocks and
Patterns
[0133] The SNP haplotype blocks, SNP haplotype patterns and/or
informative SNPs identified may be used for a variety of genetic
analyses. For example, once informative SNPs have been identified,
they may be used in a number of different assays for association
studies. For example, probes may be designed for microarrays that
interrogate these informative SNPs. Other exemplary assays include,
e.g., the Taqman assays and Invader assays described supra, as well
as conventional PCR and/or sequencing techniques.
[0134] In some embodiments, as shown in step 170 of FIG. 1, the
haplotype patterns identified may be used in the above-referenced
assays to perform association studies. This may be accomplished by
determining haplotype patterns in individuals with the phenotype of
interest (for example, individuals exhibiting a particular disease
or individuals who respond in a particular manner to administration
of a drug) and comparing the frequency of the haplotype patterns in
these individuals to the haplotype pattern frequency in a control
group of individuals. Preferably, such SNP haplotype pattern
determinations are genome-wide; however, it may be that only
specific regions of the genome are of interest, and the SNP
haplotype patterns of those specific regions are used. In addition
to the other embodiments of the methods of the present invention
disclosed herein, the methods additionally allow for the
"dissection" of a phenotype. That is, a particular phenotype may
result from two or more different genetic bases. For example,
obesity in one individual may be the result of a defect in Gene X,
while the obesity phenotype in a different individual may be the
result of mutations in Gene Y and Gene Z. Thus, the genome scanning
capabilities of the present invention allow for the dissection of
varying genetic bases for similar phenotypes. Once specific regions
of the genome are identified as being associated with a particular
phenotype, these regions may be used as drug discovery targets
(step 180 of FIG. 1) or as diagnostic markers (step 190 of FIG.
1).
[0135] As described in the previous paragraph, one method of
conducting association studies is to compare the frequency of SNP
haplotype patterns in individuals with a phenotype of interest to
the SNP haplotype pattern frequency in a control group of
individuals. In a preferred method, informative SNPs are used to
make the SNP haplotype pattern comparison. The approach of using
informative SNPs has tremendous advantage over other whole genome
scanning or genotyping methods known in the art to date, for
instead of reading all 3 billion bases of each individual's genome
or even reading the 3-4 million common SNPs that may be found-only
informative SNPs from a sample population need to be determined.
Reading these particular, informative SNPs provides sufficient
information to allow statistically accurate association data to be
extracted from specific experimental populations, as described
above.
[0136] FIG. 8 illustrates an embodiment of one method of
determining genetic associations using the methods of the present
invention. In step 800, the frequency of informative SNPs is
determined for genomes of a control population. In step 810, the
frequency of informative SNPs is determined for genomes of a
clinical population. Steps 800 and 810 may be performed by using
the aforementioned SNP assays to analyze the informative SNPs in a
population of individuals. In step 820, the informative SNP
frequencies from steps 800 and 810 are compared. Frequency
comparisons may be made, for example, by determining the minor
allele frequency (number of individuals with a particular minor
allele divided by the total number of individuals) at each
informative SNP location in each population and comparing these
minor allele frequencies. In step 830, the informative SNPs
displaying a difference between the frequency of occurrence in the
control versus clinical populations are selected for analysis. Once
informative SNPs are selected, the SNP haplotype blocks that
contain the informative SNPs are identified, which in turn
identifies the genomic region of interest (step 840). The genomic
regions are analyzed by genetic or biological methods known in the
art (step 850), and the regions are analyzed for possible use as
drug discovery targets (step 860) or as diagnostic markers (step
870), as described in detail below.
[0137] Uses of Identified Genomic Sequences
[0138] Once a genetic locus or multiple loci in the genome are
associated with a particular phenotypic trait--for example, a
disease susceptibility locus--the gene or genes or regulatory
elements responsible for the trait can be identified. These genes
or regulatory elements may then be used as therapeutic targets for
the treatment of the disease, as shown in step 180 of FIG. 1 or
step 860 of FIG. 8. The genomic sequences identified by the methods
of the present invention may be genic or nongenic sequences. The
term "gene" intended to mean the open reading frame (ORF) encoding
specific polypeptides, intronic regions, as well as adjacent 5' and
3' non-coding nucleotide sequences involved in the regulation of
expression of the gene up to about 10 kb beyond the coding region,
but possibly further in either direction. The ORFs of an identified
gene may affect the disease state due to their effect on protein
structure. Alternatively, the noncoding sequences of the identified
gene or nongenic sequences may affect the disease state by
impacting the level of expression or specificity of expression of a
protein. Generally, genomic sequences are studied by isolating the
identified gene substantially free of other nucleic acid sequences
that do not include the genic sequence. The DNA sequences are used
in a variety of ways. For example, the DNA may be used to detect or
quantify expression of the gene in a biological specimen. The
manner in which cells are probed for the presence of particular
nucleotide sequences is well established in the literature and does
not require elaboration here, however, see, e.g., Sambrook, et al.,
Molecular Cloning: A Laboratory Manual (Cold Spring Harbor
Laboratory, New York) (1989)
[0139] In addition, the sequence of the gene, including flanking
promoter regions and coding regions, may be mutated in various ways
known in the art to generate targeted changes in expression level,
or changes in the sequence of the encoded protein, etc. The
sequence changes may be substitutions, insertions, translocations
or deletions. Deletions may include large changes, such as
deletions of an entire domain or exon. Techniques for in vitro
mutagenesis of cloned genes are known. Examples of protocols for
site specific mutagenesis may be found in Gustin, et al.,
Biotechniques 14:22 (1993); Barany, Gene 37:111-23 (1985);
Colicelli, et al., Mol. Gen. Genet. 199:537-9 (1985); Prentki, et
al., Gene 29:303-13 (1984); Sambrook, et al., Molecular Cloning: A
Laboratory Manual (Cold Spring Harbor Press) pp. 15.3-15.108
(1989); Weiner, et al., Gene 126:35-41 (1993); Sayers, et al.,
Biotechniques 13:592-6 (1992); Jones and Winistorfer, Biotechniques
12:528-30 (1992); and Barton, et al., Nucleic Acids Res. 18:7349-55
(1990). Such mutated genes may be used to study structure/function
relationships of the protein product, or to alter the properties of
the protein that affect its function or regulation.
[0140] The identified gene may be employed for producing all or
portions of the resulting polypeptide. To express a protein
product, an expression cassette incorporating the identified gene
may be employed. The expression cassette or vector generally
provides a transcriptional and translational initiation region,
which may be inducible or constitutive, where the coding region is
operably linked under the transcriptional control of the
transcriptional initiation region, and a transcriptional and
translational termination region. These control regions may be
native to the identified gene, or may be derived from exogenous
sources.
[0141] The peptide may be expressed in prokaryotes or eukaryotes in
accordance with conventional methods, depending upon the purpose
for expression. For large scale production of the protein, a
unicellular organism, such as E. coli, B. subtilis, S. cerevisiae,
insect cells in combination with baculovirus vectors, or cells of a
higher organism such as vertebrates, particularly mammals, e.g. COS
7 cells, may be used as the expression host cells. In many
situations, it may be desirable to express the gene in eukaryotic
cells, where the gene will benefit from native folding and
post-translational modifications. Small peptides also can be
synthesized in the laboratory. With the availability of the protein
or fragments thereof in large amounts, the protein may be isolated
and purified in accordance with conventional ways. A lysate may be
prepared of the expression host and the proteins or fragments
thereof purified using HPLC, exclusion chromatography, gel
electrophoresis, affinity chromatography, or other purification
techniques.
[0142] An expressed protein may be used for the production of
antibodies, where short fragments induce the expression of
antibodies specific for the particular polypeptide (monoclonal
antibodies), and larger fragments or the entire protein allow for
the production of antibodies over the length of the polypeptide
(polyclonal antibodies). Antibodies are prepared in accordance with
conventional ways, where the expressed polypeptide or protein is
used as an immunogen, by itself or conjugated to known immunogenic
carriers, e.g. KLH, pre-S HBsAg, other viral or eukaryotic
proteins, or the like. Various adjuvants may be employed, with a
series of injections, as appropriate. For monoclonal antibodies,
after one or more booster injections, the spleen is isolated, the
lymphocytes are immortalized by cell fusion and screened for high
affinity antibody binding. The immortalized cells, i.e.,
hybridomas, producing the desired antibodies may then be expanded.
For further description, see Monoclonal Antibodies: A Laboratory
Manual, Harlow and Lane, eds. (Cold Spring Harbor Laboratories,
Cold Spring Harbor, N.Y.) (1988). If desired, the mRNA encoding the
heavy and light chains may be isolated and mutagenized by cloning
in E. coli, and the heavy and light chains mixed to further enhance
the affinity of the antibody. Alternatives to in vivo immunization
as a method of raising antibodies include binding to phage
"display" libraries, usually in conjunction with in vitro affinity
maturation.
[0143] The identified genes, gene fragments, or the encoded protein
or protein fragments may be useful in gene therapy to treat
degenerative and other disorders. For example, expression vectors
may be used to introduce the identified gene into a cell. Such
vectors generally have convenient restriction sites located near
the promoter sequence to provide for the insertion of nucleic acid
sequences in a recipient genome. Transcription cassettes may be
prepared comprising a transcription initiation region, the target
gene or fragment thereof, and a transcriptional termination region.
The transcription cassettes may be introduced into a variety of
vectors, e.g. plasmid; retrovirus, e.g. lentivirus; adenovirus; and
the like, where the vectors are able to be transiently or stably
maintained in the cells. The gene or protein product may be
introduced directly into tissues or host cells by any number of
routes, including viral infection, microinjection, or fusion of
vesicles. Jet injection may also be used for intramuscular
administration, as described by Furth, et al., Anal. Biochem,
205:365-68 (1992). Alternatively, the DNA may be coated onto gold
microparticles, and delivered intradermally by a particle
bombardment device, or "gene gun" as described in the literature
(see, for example, Tang, et al., Nature, 356:152-54 (1992)).
[0144] Antisense molecules can be used to down-regulate expression
of the identified gene in cells. The antisense reagent may be
antisense oligonucleotides, particularly synthetic antisense
oligonucleotides having chemical modifications, or nucleic acid
constructs that express such antisense molecules as RNA. A
combination of antisense molecules may be administered, where a
combination may comprise multiple different sequences.
[0145] As an alternative to antisense inhibitors, catalytic nucleic
acid compounds, e.g., ribozymes, anti-sense conjugates, etc., may
be used to inhibit gene expression. Ribozymes may be synthesized in
vitro and administered to the patient, or may be encoded on an
expression vector, from which the ribozyme is synthesized in the
targeted cell (for example, see International patent application WO
9523225, and Beigelman, et al., Nucl. Acids Res. 23:4434-42
(1995)). Examples of oligonucleotides with catalytic activity are
described in WO 9506764. Conjugates of antisense oligonucleotides
with a metal complex, e.g. terpyridylCu(II), capable of mediating
mRNA hydrolysis are described in Bashkin, et al., Appl. Biochem.
Biotechnol. 54:43-56 (1995).
[0146] In addition to using the identified sequences for gene
therapy, the identified nucleic acids can be used to generate
genetically modified non-human animals to create animal models of
diseases or to generate site-specific gene modifications in cell
lines for the study of protein function or regulation. The term
"transgenic" is intended to encompass genetically modified animals
having an exogenous gene that is stably transmitted in the host
cells where, for example, the gene may be altered in sequence to
produce a modified protein, or may be a reporter gene operably
linked to an exogenous promoter. Transgenic animals may be made
through homologous recombination, where the endogenous gene locus
is altered, replaced or otherwise disrupted. Alternatively, a
nucleic acid construct may be randomly integrated into the genome.
Vectors for stable integration include plasmids, retroviruses and
other animal viruses, YACs, and the like. Of interest are
transgenic mammals, e.g., cows, pigs, goats, horses, etc., and,
particularly, rodents, e.g., rats, mice, etc.
[0147] Investigation of genetic function may also utilize
non-mammalian models, particularly using those organisms that are
biologically and genetically well-characterized, such as C.
elegans, D. melanogaster and S. cerevisiae. The subject gene
sequences may be used to knock-out corresponding gene function or
to complement defined genetic lesions in order to determine the
physiological and biochemical pathways involved in protein
function. Drug screening may be performed in combination with
complementation or knock-out studies, e.g., to study progression of
degenerative disease, to test therapies, or for drug discovery.
[0148] In addition, the modified cells or animals are useful in the
study of protein function and regulation. For example, a series of
small deletions and/or substitutions may be made in the identified
gene to determine the role of different domains in enzymatic
activity, cell transport or localization, etc. Specific constructs
of interest include, but are not limited to, antisense constructs
to block gene expression, expression of dominant negative genetic
mutations, and over-expression of the identified gene. One may also
provide for expression of the identified gene or variants thereof
in cells or tissues where it is not normally expressed or at
abnormal times of development. In addition, by providing expression
of a protein in cells in which it is not normally produced, one can
induce changes in cellular behavior that provide information
regarding the normal function of the protein.
[0149] Protein molecules may be assayed to investigate
structure/function parameters. For example, by providing for the
production of large amounts of a protein product of an identified
gene, one can identify ligands or substrates that bind to, modulate
or mimic the action of that protein product. Drug screening
identifies agents that provide, e.g., a replacement or enhancement
for protein function in affected cells, or for agents that modulate
or negate protein function. The term "agent" as used herein
describes any molecule, e.g. protein or small molecule, with the
capability of altering, mimicking or masking, either directly or
indirectly, the physiological function of an identified gene or
gene product. Generally a plurality of assay mixtures are run in
parallel with different concentrations of the agent to obtain a
differential response to the various concentrations. Typically, one
of these concentrations serves as a negative control, i.e., at zero
concentration or below the level of detection.
[0150] A wide variety of assays may be used for this purpose,
including labeled in vitro protein-protein binding assays,
protein-DNA binding assays, electrophoretic mobility shift assays,
immunoassays for protein binding, and the like. Also, all or a
fragment of the purified protein may be used for determination of
three-dimensional crystal structure, which can be used for
determining the biological function of the protein or a part
thereof, modeling intermolecular interactions, membrane fusion,
etc.
[0151] Candidate agents encompass numerous chemical classes, though
typically they are organic molecules or complexes, preferably small
organic compounds, having a molecular weight of more than 50 and
less than about 2,500 daltons. Candidate agents comprise functional
groups necessary for structural interaction with proteins,
particularly hydrogen bonding, and typically include at least an
amine, carbonyl, hydroxyl or carboxyl group, and frequently at
least two of the functional chemical groups. The candidate agents
often comprise cyclical carbon or heterocyclic structures and/or
aromatic or polyaromatic structures substituted with one or more of
the above functional groups. Candidate agents are also found among
biomolecules including, but not limited to: peptides, saccharides,
fatty acids, steroids, purines, pyrimidines, derivatives,
structural analogs or combinations thereof.
[0152] Candidate agents are obtained from a wide variety of sources
including libraries of synthetic or natural compounds. For example,
numerous means are available for random and directed synthesis of a
wide variety of organic compounds and biomolecules, including
expression of randomized oligonucleotides and oligopeptides.
Alternatively, libraries of natural compounds in the form of
bacterial, fungal, plant and animal extracts are available or
readily produced. Additionally, natural or synthetically produced
libraries and compounds are readily modified through conventional
chemical, physical and biochemical means, and may be used to
produce combinatorial libraries. Known pharmacological agents may
be subjected to directed or random chemical modifications, such as
acylation, alkylation, esterification, amidification, etc., to
produce structural analogs.
[0153] Where the screening assay is a binding assay, one or more of
the molecules may be coupled to a label, where the label can
directly or indirectly provide a detectable signal. Various labels
include radioisotopes, fluorescers, chemiluminescers, enzymes,
specific binding molecules, particles, e.g., magnetic particles,
and the like. Specific binding molecules include pairs, such as
biotin and streptavidin, digoxin and antidigoxin, etc. For the
specific binding members, the complementary member would normally
be labeled with a molecule that provides for detection, in
accordance with known procedures.
[0154] A variety of other reagents may be included in the screening
assay. These include reagents like salts, neutral proteins, e.g.,
albumin, detergents, etc that are used to facilitate optimal
protein-protein binding and/or reduce non-specific or background
interactions. Reagents that improve the efficiency of the assay,
such as protease inhibitors, nuclease inhibitors, anti-microbial
agents, etc., may be used.
[0155] Agents may be combined with a pharmaceutically acceptable
carrier, including any and all solvents, dispersion media,
coatings, anti-oxidant, isotonic and absorption delaying agents and
the like. The use of such media and agents for pharmaceutically
active substances is well known in the art. Except insofar as any
conventional media or agent is incompatible with the active
ingredient, its use in the therapeutic compositions and methods
described herein is contemplated. Supplementary active ingredients
can also be incorporated into the compositions.
[0156] The formulation may be prepared for use in various methods
for administration. The formulation may be given orally, by
inhalation, or may be injected, e.g. intravascular, intratumor,
subcutaneous, intraperitoneal, intramuscular, etc. The dosage of
the therapeutic formulation will vary widely, depending upon the
nature of the disease, the frequency of administration, the manner
of administration, the clearance of the agent from the host, and
the like. The initial dose may be larger, followed by smaller
maintenance doses. The dose may be administered as infrequently as
once, weekly or biweekly, or fractionated into smaller doses and
administered daily, semi-weekly, etc., to maintain an effective
dosage level. In some cases, oral administration will require a
different dose than if administered intravenously. Identified
agents of the invention can be incorporated into a variety of
formulations for therapeutic administration. More particularly, the
complexes can be formulated into pharmaceutical compositions by
combination with appropriate, pharmaceutically acceptable carriers
or diluents, and may be formulated into preparations in solid,
semi-solid, liquid or gaseous forms, such as tablets, capsules,
powders, granules, ointments, solutions, suppositories, injections,
inhalants, gels, microspheres, and aerosols. As such,
administration of the agents can be achieved in various ways.
Agents may be systemic after administration or may be localized by
the use of an implant that acts to retain the active dose at the
site of implantation.
[0157] The following methods and excipients are merely exemplary
and are in no way limiting. For oral preparations, an agent can be
used alone or in combination with appropriate additives to make
tablets, powders, granules or capsules, for example, with
conventional additives, such as lactose, mannitol, corn starch or
potato starch; with binders, such as crystalline cellulose,
cellulose derivatives, acacia, corn starch or gelatins; with
disintegrators, such as corn starch, potato starch or sodium
carboxymethylcellulose; with lubricants, such as talc or magnesium
stearate; and if desired, with diluents, buffering agents,
moistening agents, preservatives and flavoring agents.
[0158] Additionally, agents may be formulated into preparations for
injections by dissolving, suspending or emulsifying them in an
aqueous or nonaqueous solvent, such as vegetable or other similar
oils, synthetic aliphatic acid glycerides, esters of higher
aliphatic acids or propylene glycol; and if desired, with
conventional additives such as solubilizers, isotonic agents,
suspending agents, emulsifying agents, stabilizers and
preservatives. Further, agents may be utilized in aerosol
formulation to be administered via inhalation. The agents
identified by the present invention can be formulated into
pressurized acceptable propellants such as dichlorodifluoromethane,
propane, nitrogen and the like. Alternatively, agents may be made
into suppositories by mixing with a variety of bases such as
emulsifying bases or water-soluble bases. Further, identified
agents of the present invention can be administered rectally via a
suppository. The suppository can include vehicles such as cocoa
butter, carbowaxes and polyethylene glycols, which melt at body
temperature, yet are solidified at room temperature.
[0159] Implants for sustained release formulations are well-known
in the art. Implants are formulated as microspheres, slabs, etc.
with biodegradable or non-biodegradable polymers. For example,
polymers of lactic acid and/or glycolic acid form an erodible
polymer that is well-tolerated by the host. The implant containing
identified agents of the present invention may be placed in
proximity to the site of action, so that the local concentration of
active agent is increased relative to the rest of the body. Unit
dosage forms for oral or rectal administration such as syrups,
elixirs, and suspensions may be provided wherein each dosage unit,
for example, teaspoonful, tablespoonful, gel capsule, tablet or
suppository, contains a predetermined amount of the compositions of
the present invention. Similarly, unit dosage forms for injection
or intravenous administration may comprise the compound of the
present invention in a composition as a solution in sterile water,
normal saline or another pharmaceutically acceptable carrier. The
specifications for the novel unit dosage forms of the present
invention depend on the particular compound employed and the effect
to be achieved, and the pharmacodynamics associated with each
active agent in the host.
[0160] The pharmaceutically acceptable excipients, such as
vehicles, adjuvants, carriers or diluents, are readily available to
the public. Moreover, pharmaceutically acceptable auxiliary
substances, such as pH adjusting and buffering agents, tonicity
adjusting agents, stabilizers, wetting agents and the like, are
readily available to the public.
[0161] A therapeutic dose of an identified agent is administered to
a host suffering from a disease or disorder. Administration may be
topical, localized or systemic, depending on the specific disease.
The compounds are administered at an effective dosage such that
over a suitable period of time the disease progression may be
substantially arrested. It is contemplated that the composition
will be obtained and used under the guidance of a physician for in
vivo use. The dose will vary depending on the specific agent and
formulation utilized, type of disorder, patient status, etc., such
that it is sufficient to address the disease or symptoms thereof,
while minimizing side effects. Treatment may be for short periods
of time, e.g., after trauma, or for extended periods of time, e.g.,
in the prevention or treatment of schizophrenia.
[0162] The SNPs identified by the present invention may be used to
analyze the expression pattern of an associated gene and the
expression pattern correlated to a phenotypic trait of the organism
such as disease susceptibility or drug responsiveness. The
expression pattern in various tissues can be determined and used to
identify ubiquitous expression patterns, tissue specific expression
patterns, temporal expression patterns and expression patterns
induced by various external stimuli such as chemicals or
electromagnetic radiation. Such determinations would provide
information regarding function of the gene and/or its protein
product.
[0163] The newly identified sequences also may be used as
diagnostic markers, i.e., to predict a phenotypic characteristic
such as disease susceptibility or drug responsiveness. In addition,
the methods of the present invention may be used to stratify
populations for clinical studies. As such, the genes or fragments
thereof may be used as probes to determine whether the same nucleic
acid sequence is present in the genome of an organism being tested.
In addition, the probes may be used to monitor RNA or mRNA levels
within the organism to be tested or a part thereof, such as a
specific tissue or organ, so as to determine the expression level
of the marker where the expression level can be correlated to a
particular phenotypic characteristic of the organism. Likewise, the
marker may be assayed at the protein level using any customary
technique such as immunological methods--Western blots, radioimmune
precipitation and the like--or activity based assays measuring an
activity associated with the gene product. Moreover, when a
phenotype cannot clearly distinguish between similar diseases
having different genetic bases, the methods of the present
invention can be used to identify correctly the disease.
[0164] Also, it should be apparent that the methods of the present
invention can be used on organisms aside from humans. For example,
when the organism is an animal, the methods of the invention may be
used to identify loci associated, e.g., with disease resistance/or
susceptibility, environmental tolerance, drug response or the like,
and when the organism is a plant, the method of the invention may
be used to identify loci associated with disease resistance/or
susceptibility, environmental tolerance and or herbicide
resistance.
[0165] It is to be understood that this invention is not limited to
the particular methodology, protocols, cell lines, animal species
or genera, and reagents described, as such may vary. It is also to
be understood that the terminology used herein is for the purpose
of describing particular embodiments only, and is not intended to
limit the scope of the present invention, which will be limited
only by the appended claims.
[0166] Databases
[0167] The present invention includes databases containing
information concerning variations, for instance, information
concerning SNPs, SNP haplotype blocks, SNP haplotype patterns and
informative SNPs. In some embodiments, the databases of the present
invention may comprise information on one or more haplotype
patterns associated with one or more phenotypic traits. Databases
may also contain information associated with a given variation such
as descriptive information about the general genomic region in
which the variation occurs, such as whether the variation is
located in a known gene, whether there are known genes, gene
homologs or regulatory regions nearby and the like.
[0168] Other information that may be included in the databases of
the present invention include, but are not limited to, SNP sequence
information, descriptive information concerning the clinical status
of a tissue sample analyzed for SNP haplotype patterns, or the
clinical status of the patient from which the sample was derived.
The database may be designed to include different parts, for
instance a variation database, a SNP database, a SNP haplotype
block or SNP haplotype pattern database and an informative SNP
database. Methods for the configuration and construction of
databases are widely available, for instance, see Akerblom et al.,
(1999) U.S. Pat. No. 5,953,727, which is herein incorporated by
reference in its entirety.
[0169] The databases of the invention may be linked to an outside
or external database. FIG. 9 shows an exemplary computer network
that is suitable for the databases and executing the software of
the present invention. A computer workstation 902 is connected with
the application/data server(s) 906 through a local area network
(LAN), such as an ethernet 905. A printer 904 may be connected
directly to the workstation or to the Ethernet 905. The LAN may be
connected to a wide area network (WAN), such as the internet 908
via a gateway server 907 which may also serve as a firewall between
the WAN 908 and the LAN 905. In preferred embodiments, the
workstation may communicate with outside data sources, such as The
SNP Consortium (TSC) or the National Center for Biotechnology
Information 909, through the internet 908.
[0170] Any appropriate computer platform may be used to perform the
necessary comparisons between SNP haplotype blocks or patterns,
associated phenotypes, any other information in the database or
information provided as an input. For example, a large number of
computer workstations are available from a variety of
manufacturers, such has those available from Silicon Graphics.
Client-server environments, database servers and networks are also
widely available and are appropriate platforms for the databases of
the invention.
[0171] The databases of the invention may also be used to present
information identifying the SNP haplotype pattern in an individual
and such a presentation may be used to predict one or more
phenotypic traits of the individual. Such methods may be used to
predict the disease susceptibility/resistance and/or drug response
of the individual. Further, the databases of the present invention
may comprise information relating to the expression level of one or
more of the genes associated with the variations of the
invention.
[0172] The following examples describe specific embodiments of the
present invention and the materials and methods are illustrative of
the invention and are not intended to limit the scope of the
invention.
EXAMPLE 1
Preparation of Somatic Cell Hybrids
[0173] Standard procedures in somatic cell genetics were used to
separate human DNA strands (chromosomes) from a diploid state to a
haploid state. In this case, a diploid human lymphoblastoid cell
line that was wildtype for the thymidine kinase gene was fused to a
diploid hamster fibroblast cell line containing a mutation in the
thymidine kinase gene. A sub-population of the resulting cells were
hybrid cells containing human chromosomes. Hamster cell line A23
cells were pipetted into a centrifuge tube containing 10 ml DMEM in
which 10% fetal bovine serum (FBS)+1.times. Pen/Strep+10% glutamine
were added, centrifuged at 1500 rpm for 5 minutes, resuspended in 5
ml of RPMI and pipetted into a tissue culture flask containing 15
ml RPMI medium. The lymphoblastoid cells were grown at 37.degree.
C. to confluence. At the same time, human lymphoblastoid cells were
pipetted into a centrifuge tube containing 10 ml RPMI in which 15%
FBCS+1.times. Pen/Strep+10% glutamine were added, centrifuged at
1500 rpm for 5 minutes, resuspended in 5 ml of RPMI and pipetted
into a tissue culture flask containing 15 ml RPMI. The
lymphoblastoid cells were grown at 37.degree. C. to confluence.
[0174] To prepare the A23 hamster cells, the growth medium was
aspirated and the cells were rinsed with 10 ml PBS. The cells were
then trypsinized with 2 ml of trypsin, divided onto 3-5 plates of
fresh medium (DMEM without HAT) and incubated at 37.degree. C. The
lymphoblastoid cells were prepared by transferring the culture into
a centrifuge tube and centrifuging at 1500 rpm for 5 minutes,
aspirating the growth medium, resuspending the cells in 5 ml RPMI
and pipetting 1 to 3 ml of cells into 2 flasks containing 20 ml
RPMI.
[0175] To achieve cell fusion, approximately 8-10.times.10.sup.6
lymphoblastoid cells were centrifuged at 1500 rpm for 5 min. The
cell pellet was then rinsed with DMEM by resuspending the cells,
centrifuging them again and aspirating the DMEM. The lymphoblastoid
cells were then resuspended in 5 ml fresh DMEM. The recipient A23
hamster cells had been grown to confluence and split 3-4 days
before the fusion and were, at this point, 50-80% confluent. The
old media was removed and the cells were rinsed three times with
DMEM, trypsinized, and finally suspended in 5 ml DMEM. The
lymphoblastoid cells were slowly pipetted over the recipient A23
cells and the combined culture was swirled slowly before incubating
at 37.degree. C. for 1 hour. After incubation, the media was gently
aspirated from the A23 cells, and 2 ml room temperature PEG 1500
was added by touching the edge of the plate with a pipette and
slowly adding PEG to the plate while rotating the plate with the
other hand. It took approximately one minute to add all the PEG in
one full rotation of the plate. Next, 8 ml DMEM was added down the
edge of the plate while rotating the plate slowly. The PEG/DMEM
mixture was aspirated gently from the cells and then 8 ml DMEM was
used to rinse the cells. This DMEM was removed and 10 ml fresh DMEM
was added and the cells were incubated for 30 min. at 37.degree. C.
Again the DMEM was aspirated from the cells and 10 ml DMEM in which
10% FBCS and 1.times. Pen/Strep were added, was added to the cells,
which were then allowed to incubate overnight.
[0176] After incubation, the media was aspirated and the cells were
rinsed with PBS. The cells were then trypsinized and divided among
plates containing selection media (DMEM in which 10% FBS+1.times.
Pen/Strep+1.times. HAT were added) so that each plate received
approximately 100,000 cells. The media was changed on the third day
following plating. Colonies were picked and placed into 24-well
plates upon becoming visible to the naked eye (day 9-14). If a
picked colony was confluent within 5 days, it was deemed healthy
and the cells were trypsinized and moved to a 6-well plate.
[0177] DNA and stock hybrid cell cultures were prepared from the
cells from the 6-well plate cultures. The cells were trypsinized
and divided between a 100 mm plate containing 10 ml selection media
and an Eppendorf tube. The cells in the tube were pelleted,
resuspended 200 .mu.l PBX and DNA was isolated using a Qiagen DNA
mini kit at a concentration of <5 million cells per spin column.
The 100 mm plate was grown to confluence, and the cells were either
continued in culture or frozen.
EXAMPLE 2
Selecting Haploid Hybrids
[0178] Scoring for the presence, absence and diploid/haploid state
of human chromosomes in each hybrid was performed using the
Affymetrix, HuSNP genechip (Affymetrix, Inc,. of Santa Clara,
Calif., HuSNP Mapping Assay, reagent kit and user manual,
Affymetrix Part No. 900194), which can score 1494 markers in a
single chip hybridization. As controls, the hamster and human
diploid lymphoblastoid cell lines were screened using the HuSNP
chip hybridization assay. Any SNPs which were heterozygous in the
parent lymphoblastoid diploid cell line were scored for haploidy in
each fusion cell line. Assume that "A" and "B" are alternative
variants at each SNP location. By comparing the markers that were
present as "AB" heterozygous in the parent diploid cell line to the
same markers present as "A" or "B" (hemizygous) in the hybrids, the
human DNA strands which were in the haploid state in each hybrid
line was determined.
[0179] FIG. 11 shows results after two human/hamster cell hybrids
(Hybrid 1 and Hybrid 2) are tested for selected markers on human
chromosome 21. The first column lists the HuSNP chip marker
designations. The second column reports whether a signal was
obtained when the hamster cell nucleic acid (no fusion) was used
for hybridization with a HuSNP chip. As expected, there was no
signal for any marker in the hamster cell sample. The third column
reports which variants for each marker were detected ("A", "B" or
"AB") in the diploid parent human lymphoblastoid cell line, CPD17.
In some instances, only an A variant was present, in some instances
only a B variant was present, and in some cases the CPD17 cells
were heterozygous ("AB") for the variants. The last two columns
report the result when nucleic acid samples from two human/hamster
hybrids (Hybrid 1 and Hybrid 2) are hybridized with the HuSNP chip.
Note in cases where only A variants were present in the parent
CPD17 cell line, only A variants were transferred in the fusion. In
cases where only B variants were present in the parent CPD17 cell
line, only B variants were transferred in the fusion. In cases
where the CPD17 cell line was heterozygous, an A variant was
transferred to some fusion clones, and a B variant was transferred
to other fusion clones. It should be understood, however, that
often only portions of chromosomes are present in the hybrid cell
lines resulting from this fusion process, that some hybrids may be
diploid for some human chromosomes or portions thereof, that some
hybrids may be haploid for other human chromosomes or portions
thereof, and some hybrids may not have either variant of some
chromosomes. Hybrids containing only one variant of a particular
human chromosome (for instance, chromosome 21) were selected for
analysis. Even more preferably, hybrids containing a whole
chromosome (as opposed to only a portion thereof) were selected for
analysis.
EXAMPLE 3
Long Range PCR
[0180] DNA from the hamster/human cell hybrids was used to perform
long-range PCR assays. Long range PCR assays are known generally in
the art and have been described, for example, in the standard long
range PCR protocol from the Boehringer Mannheim Expand Long Range
PCR Kit, incorporated herein by reference or all purposes.
[0181] Primers used for the amplification reactions were designed
in the following way: a given sequence, for example the 23 megabase
contig on chromosome 21, was entered into a software program known
in the art herein called "repeat masker" which recognizes sequences
that are repeated in the genome (e.g., Alu and Line elements)(see,
A. F. A. Smit and P. Green,
www.genome.washington.edu/uwgc/analysistools/repeatmask,
incorporated herein by reference). The repeated sequences were
"masked" by the program by substituting each specific nucleotide of
the repeated sequence (A, T, G or C) with "N". The sequence output
after this repeat mask substitution was then fed into a
commercially available primer design program (Oligo 6.23) to select
primers that were greater than 30 nucleotides in length and had
melting temperatures of over 65.degree. C. The designed primer
output from Oligo 6.23 was then fed into a program which then
"chose" primer pairs which would PCR amplify a given region of the
genome but have minimal overlap with the adjacent PCR products. The
success rate for long range PCR using commercially available
protocols and this primer design was at least 80%, and greater than
95% success was achieved on some portions of human chromosomes.
[0182] An illustrative protocol for long range PCR uses the Expand
Long Template PCR System from Boehringer Mannheim Cat.# 1681 834,
1681 842, or 1759 060. In the procedure each 50 .mu.L PCR reaction
requires two master mixes. In a specific example, Master Mix 1 was
prepared for each reaction in 1.5 ml microfuge tubes on ice and
includes a final volume of 19 .mu.L of Molecular Biology Grade
Water (Bio Whittaker, Cat.# 16-001Y); 2.5 .mu.L 10 mM dNTP set
containing dATP, dCTP, dGTP, and dTTP at 10 mM each (Life
Technologies Cat.# 10297-018) for a final concentration of 400
.mu.M of each dNTP; and 50 ng DNA template.
[0183] Master Mix 2 for all reactions was prepared and kept on ice.
For each PCR reaction Master Mix 2 includes a final volume of 25
.mu.L of Molecular Biology Grade Water (Bio Whittaker); 5 .mu.L
10.times. PCR buffer 3 containing 22.50 mM MgCl.sub.2 (Sigma, Cat.#
M 10289); 2.5 .mu.L 10 mM MgCl.sub.2 (for a final MgCl.sub.2
concentration of 2.75 mM); and 0.75 .mu.L enzyme mix (added
last)
[0184] Six microliters of premixed primers (containing 2.5 .mu.L of
Master Mix 1) were added to appropriate tubes, then 25 .mu.L of
Master Mix 2 was added to each tube. The tubes were capped, mixed,
centrifuged briefly and returned to ice. At this point, the PCR
cycling was begun according to the following program: step 1:
94.degree. C. for 3 min to denature template; step 2: 94.degree. C.
for 30 sec; step 3: annealing for 30 sec at a temperature
appropriate for the primers used; step 4: elongation at 68.degree.
C. for 1 min/kb of product; step 5: repetition of steps 2-4 38
times for a total of 39 cycles; step 6: 94.degree. C. for 30 sec;
step 7: annealing for 30 sec; step 8: elongation at 68.degree. C.
for 1 min/kb of product plus 5 additional minutes; and step 9: hold
at 4.degree. C. Alternatively, a two-step PCR would be performed:
step 1: 94.degree. C. for 3 min to denature template; step 2:
94.degree. C. for 30 sec; step 3: annealing and elongation at
68.degree. C. for 1 min/kb of product; step 4: repetition of steps
2-3 38 times for a total of 39 cycles; step 5:94.degree. C. for 30
sec; step 6: annealing and elongation at 68.degree. C. for 1 min/kb
of product plus 5 additional minutes; and step 7: hold at 4.degree.
C.
[0185] Results of the long range PCR amplification reaction for
various regions on human chromosomes 14 and 22 were visualized on
ethidium bromide-stained agarose gels (FIG. 12). The long range PCR
amplification methods of the present invention routinely produced
amplified fragments having an average size of about 8 kb, and
appeared to fail to amplify genomic regions in only rare cases (see
G11 on the chromosome 22 gel).
EXAMPLE 4
Wafer Design, Manufacture, Hybridization and Scanning
[0186] The set of oligonucleotide probes to be contained on an
oligonucleotide array (chip or wafer) was defined based on the
human DNA strand sequence to be queried. The oligonucleotide
sequences were based on consensus sequences reported in publicly
available databases. Once the probe sequences were defined,
computer algorithms were used to design photolithographic masks for
use in manufacturing the probe-containing arrays. Arrays were
manufactured by a light-directed chemical synthesis processes which
combines solid-phase chemical synthesis with photolithographic
fabrication techniques. See, for example, WO 92/10092, or U.S. Pat.
Nos. 5,143,854; 5,384,261; 5,405,783; 5,412,087; 5,424,186;
5,445,934; 5,744,305; 5,800,992; 6,040,138; 6,040,193, all of which
are incorporated herein by reference in their entireties for all
purposes. Using a series of photolithographic masks to define
exposure sites on the glass substrate (wafer) followed by specific
chemical synthesis steps, the process constructed high-density
areas of oligonucleotide probes on the array, with each probe in a
predefined position. Multiple probe regions were synthesized
simultaneously and in parallel.
[0187] The synthesis process involved selectively illuminating a
photo-protected glass substrate by passing light through a
photolithographic mask wherein chemical groups in unprotected areas
were activated by the light. The selectively-activated substrate
wafers were then incubated with a chosen nucleoside, and chemical
coupling occurred at the activated positions on the wafer. Once
coupling took place, a new mask pattern was applied and the
coupling step was repeated with another chosen nucleoside. This
process was repeated until the desired set of probes was obtained.
In one specific example, 25-mer oligonucleotide probes were used,
where the thirteenth base was the base to be queried. Four probes
were used to interrogate each nucleotide present in each
sequence--one probe complementary to the sequence and three
mismatch probes identical to the complementary probe except for the
thirteenth base. In some cases, at least 10.times.10.sup.6 probes
were present on each array.
[0188] Once fabricated, the arrays were hybridized to the products
from the long range PCR reactions performed on the hamster-human
cell hybrids. The samples to be analyzed were labeled and incubated
with the arrays to allow hybridization of the sample to the probes
on the wafer.
[0189] After hybridization, the array was inserted into a confocal,
high performance scanner, where patterns of hybridization were
detected. The hybridization data were collected as light emitted
from fluorescent reporter groups already incorporated into the PCR
products of the sample, which was bound to the probes. Sequences
present in the sample that are complimentary to probes on the wafer
hybridized to the wafer more strongly and produced stronger signals
than those sequences that had mismatches. Since the sequence and
position of each probe on the array was known, by complementarity,
the identity of the variation in the sample nucleic acid applied to
the probe array was identified. Scanners and scanning techniques
used in the present invention are known to those skilled in the art
and are disclosed in, e.g., U.S. Pat. No. 5,981,956 drawn to
microarray chips, U.S. Pat. No. 6,262,838 and U.S. Pat. No.
5,459,325. U.S. Ser. No. In addition, 60/223,278 filed on Aug. 3,
2000, and non-provisional application claiming priority to U.S.
Ser. No. 60/223,278 filed on Aug. 3, 2001, drawn to scanners and
techniques for whole wafer scanning, are also incorporated herein
by reference in their entireties for all purposes.
EXAMPLE 5
Determination of SNP Haplotypes on Human Chromosome 21
[0190] Twenty independent copies of chromosome 21, representing
African, Asian, and Caucasian chromosomes were analyzed for SNP
discovery and haplotype structure. Two copies of chromosome 21 from
each individual were physically separated using a rodent-human
somatic cell hybrid technique (FIG. 10), discussed supra. The
reference sequence for the analysis consisted of human chromosome
21 genomic DNA sequence consisting of 32,397,439 bases. This
reference sequence was masked for repetitive sequences and the
resulting 21,676,868 bases (67%) of unique sequence were assayed
for variation with high density oligonucleotide arrays. Eight
unique oligonucleotides, each 25 bases in length, were used to
interrogate each of the unique sample chromosome 21 bases, for a
total of 1.7.times.10.sup.8 different oligonucleotides. These
oligonucleotides were distributed over a total of eight different
wafer designs using a previously described tiling strategy (Chee,
et al., Science 274:610 (1996)). Light-directed chemical synthesis
of oligonucleotides was carried out on 5 inch x 5 inch glass wafers
purchased from Affymetrix, Inc. (Santa Clara, Calif.).
[0191] Unique oligonucleotides were designed to generate 3253
minimally overlapping longe range PCR (LRPCR) products of 10 kb
average length spanning 32.4 Mb of contiguous chromosome 21 DNA,
and were prepared as described supra. For each wafer hybridization,
corresponding LRPCR products were pooled and were purified using
Qiagen tip 500 (Qiagen). A total of 280 .mu.g of purified DNA was
fragmented using 37 .mu.l of 10.times. One-Phor-All buffer PLUS
(Promega) and 1 unit of DNAase (Life Technolgies/Invitrogen) in 370
.mu.l total volume at 37.degree. C. for 10 min followed by heat
inactivation at 99.degree. C. for 10 min. The fragmented products
were end labeled using 500 units of Tdt (Boehringer Manheim) and 20
nmoles of biotin-N6-ddATP (DuPont NEN) at 37.degree. C. for 90 min
and heat inactivated at 95.degree. C. for 10 min. The labeled
samples were hybridized to the wafers in 10 mM Tris-HCL (pH 8), 3M
Tetramethylammonium chloride, 0.01% Tx-100, 10 .mu.g/ml denatured
herring sperm DNA in a total volume of 14 ml per wafer at
50.degree. C. for 14-16 hours. The wafers were rinsed briefly in
4.times. SSPE, washed three times in 6.times. SSPE for 10 min each,
stained using streptavidin R-phycoerythrin (SAPE, 5 ng/ml) at room
temp for 10 min. The signal was amplified by staining with an
antibody against streptavidin (1.25 ng/ml) and by repeating the
staining step with SAPE.
[0192] PCR products corresponding to the bases present on a single
wafer were pooled and hybridized to the wafer as a single reaction.
In total, 3.4.times.10.sup.9 oligonucleotides were synthesized on
160 wafers to scan 20 independent copies of human chromosome 21 for
DNA sequence variation. Each unique chromosome 21 was amplified
from a rodent-human hybrid cell line by using long range PCR. LRPCR
assays were designed using Oligo 6.23. primer design software with
high-moderate stringency parameters. The resulting primers were
typically 30 nucleotides in length with the melting temperature of
>65.degree. C. The range of amplicon size was from 3 kb-14 kb. A
primer database for the entire chromosome was generated and
software (ppicker) was utilized to choose a minimal set of
non-redundant primers that yield maximum coverage of chromosome 21
sequence with a minimal overlap between adjacent amplicons.
Alternatively, the primer selection method described in Example 3,
herein, was employed. LRPCR reactions were performed using the
Expand Long Template PCR Kit (Boehringer Mannheim) with minor
modifications. The wafers were scanned using a custom built
confocal scanner.
[0193] SNPs were detected as altered hybridization by using a
pattern recognition algorithm. A combination of previously
described algorithms (Wang, et al., Science 280:1077 (1998)), was
used to detect SNPs based on altered hybridization patterns. In
total, 35,989 SNPs were identified in the sample of twenty
chromosomes. The position and sequence of these human polymorphisms
have been deposited in GenBank's SNPdb. Dideoxy sequencing was used
to assess a random sample of 227 of these SNPs in the original DNA
samples, confirming 220 (97%) of the SNPs assayed. In order to
achieve this low rate of 3% false positive SNPs, stringent
thresholds were required for SNP detection on wafers that resulted
in a high false negative rate. Approximately 65% of all bases
present on the wafers yielded data of high enough quality for use
in SNP detection with 35% being discarded as being false negatives.
Consistent failure of long range PCR in all samples analyzed
accounts for 15% of the 35% false negative rate. The remaining 20%
false negatives are distributed between bases that never yield high
quality data (10%) and bases that yield high quality data in only a
fraction of the 20 chromosomes analyzed (10%). In general, it is
the sequence context of a base that dictates whether or not it will
yield high quality data. The finding that approximately 20% of all
bases give consistently poor data is very similar to the finding
that approximately 30% of bases in single dideoxy sequencing reads
of 500 bases have quality scores too low for reliable SNP detection
(Altschuler, et al., Nature 407:513 (2000)). The power to discover
rare SNPs as compared to more frequent SNPs is disproportionately
reduced in cases where only a limited number of the samples
analyzed yield high quality data for a given base. As a result, SNP
discovery by this method is biased in favor of common SNPs.
[0194] FIG. 13A shows the distribution of minor allele frequencies
of all 35,989 SNPs discovered in the sample of globally diverse
chromosomes. Genetic variation, normalized for the number of
chromosomes in the sample, was estimated with two measures of
nucleotide diversity: .pi. the average heterozygosity per site and
.theta. the population mutation parameter (see Hartl and Clark,
Principles of Population Genetics (Sinauer, Mass., 1997)). The
32,397,439 bases of finished genomic chromosome 21 DNA were divided
into 200,000 base pair segments, and the high-quality base pairs
used for SNP discovery in each segment were examined. The observed
heterozygosity of these bases was used to calculate an average
nucleotide diversity (.pi.) for each segment. The estimates of
average nucleotide diversity for the total data set (.pi.=0.000723
and .theta.=0.000798), as well as the distribution of nucleotide
diversity, measured in contiguous 200,000 base pair bins of
chromosome 21 (FIG. 13B), are within the range of values previously
described (The International SNP Map Working Group, Nature
409:928-33 (2001)).
[0195] The extent of overlap of 15,549 chromosome 21 SNPs
discovered by The SNP Consortium (TSC) was compared with the SNPs
found in this study. Of the TSC SNPs, 5,087 were found to be in
repeated DNA and were not tiled on the wafers. Of the remaining
10,462 TSC SNPs, 4705 (45%) were identified. The estimate of
.theta. was observed to be greater than the estimate of .pi. for
129 of the 162 200-kb bins of contiguous DNA sequence analyzed.
This difference is consistent with a recent expansion of the human
population and is similar to the finding of a recent study of
nucleotide diversity in human genes (Stephens, et al., Science
293:489 (2001)). It was found that 11,603 of the SNPs (32%) had a
minor allele observed a single time in the sample (singletons), as
compared with the neutral model expectation of 43% singletons given
the observed amount of nucleotide diversity (Fu and Li, Genetics
133:693 (1993)). The difference between the observed and expected
values is likely attributable to the reduced power to identify rare
as compared to common SNPs in this study as discussed above.
[0196] Over all, 47% of the 53,000 common SNPs with an allele
frequency of 10% or greater estimated to be present in 32.4 Mb of
the human genome were identified. This compares with an estimate of
18-20% of all such common SNPs present in the collection generated
by the International SNP Mapping Working Group and the SNP
Consortium. The difference in coverage is explained by the fact
that the present study used larger numbers of chromosomes for SNP
discovery. To assess the replicability of the findings, SNP
discovery was performed for one wafer design with nineteen
additional copies of chromosome 21 derived from the same diversity
panel as the original set of samples. A total of 7188 SNPs were
identified using the two sets of samples. On average, 66% of all
SNPs found in one set of samples were discovered in the second set,
consistent with previous findings (Marth, et al., Nature Genet.
27:371 (2001) and Yang, et al., Nature Genet. 26:13 (2000)). As
expected, failure of a SNP to replicate in a second set of samples
is strongly dependent on allele frequency. It was found that 80% of
SNPs with a minor allele present two or more times in a set of
samples were also found in a second set of samples, while only 32%
of SNPs with a minor allele present a single time were found in a
second set of samples. These findings suggest that the 24,047 SNPs
in the collection with a minor allele represented more than once
are highly replicable in different global samples and that this set
of SNPs is useful for defining common global haplotypes. In the
course of SNP discovery, 339 SNPs which appeared to have more than
two alleles were identified. These SNPs were not included in the
present analysis.
[0197] In addition to the replicability of SNPs in different
samples, the distance between consecutive SNPs in a collection of
SNPs is critical for defining meaningful haplotype structure.
Haplotype blocks, which can be as short as several kb, may go
unrecognized if the distance between consecutive SNPs in a
collection is large relative to the size of the actual haplotype
blocks. The collection of SNPs in this study was very evenly
distributed across the chromosome, even though repeat sequences
were not included in the SNP discovery process. FIG. 13C shows the
distribution of SNP coverage across 32,397,439 bases of finished
chromosome 21 DNA sequence. An interval is the distance between
consecutive SNPs. There are a total of 35,988 intervals for the
entire SNP set and a total of 24,046 intervals for the common SNP
set (i.e. SNPs with a minor allele present more than once in the
sample). The average distance between consecutive SNPs was 900
bases when all SNPs are considered, and 1300 bases when only the
24,047 common SNPs were considered. For this set of common SNPs,
93% of intervals between consecutive SNPs in genomic DNA, including
repeated DNA, were 4000 bases or less (again, see FIG. 13C).
[0198] The construction of haplotype blocks or patterns from
diploid data is complicated by the fact that the relationship
between alleles for any two heterozygous SNPs is not directly
observable. Consider an individual with two copies of chromosome 21
and two alleles, A and G, at one chromosome 21 SNP, as well as two
alleles, A and G, at a second chromosome 21 SNP. In such a case, it
is unclear if one copy of chromosome 21 contains allele A at the
first SNP and allele A at the second SNP, while the other copy of
chromosome 21 contains allele G at the first SNP and allele G at
the second SNP, or if one copy of chromosome 21 contains allele A
at the first SNP and allele G at the second SNP, while the other
copy of chromosome 21 contains allele G at the first SNP and allele
A at the second SNP. Current methods used to circumvent this
problem include statistical estimation of haplotype frequencies,
direct inference from family data, and allele-specific PCR
amplification over short segments.
[0199] To avoid these complexities, the present invention
characterized SNPs on haploid copies of chromosome 21 isolated in
rodent-human somatic cell hybrids were characterized, allowing
direct determination of the full haplotypes of these chromosomes.
The set of 24,047 SNPs with a minor allele represented more than
once in the data set was used to define the haplotype structure are
shown in FIG. 14. The haplotype patterns for twenty independent
globally diverse chromosomes defined by 147 common human chromosome
21 SNPs is shown. The 147 SNPs span 106 kb of genomic DNA sequence.
Each row of colored boxes represents a single SNP. The black boxes
in each row represent the major allele for that SNP, and the white
boxes represent the minor allele. Absence of a box at any position
in a row indicates missing data. Each column of colored boxes
represents a single chromosome, with the SNPs arranged in their
physical order on the chromosome. Invariant bases between
consecutive SNPs are not represented in the figure. The 147 SNPs
are divided into eighteen blocks, defined by black horizontal
lines. The position of the base in chromosome 21 genomic DNA
sequence defining the beginning of one block and the end of the
adjacent block is indicated by the numbers to the left of the
vertical black line. The expanded boxes on the right of the figure
represent a SNP block defined by 26 common SNPs spanning 19 kb of
genomic DNA. Of the seven different haplotype patterns represented
in the sample, the four most common patterns include sixteen of the
twenty chromosomes sampled (i.e. 80% of the sample). The black and
white circles indicate the allele patterns of two informative SNPs,
which unambiguously distinguish between the four common haplotypes
in this block. Although no two chromosomes shared an identical
haplotype pattern for these 147 SNPs, there are numerous regions in
which multiple chromosomes shared a common pattern. One such
region, defined by 26 SNPs spanning 19 kb, is expanded for more
detailed analysis (again, see the enlarged region of FIG. 14). This
block defines seven unique haplotype patterns in 20 chromosomes.
Despite the fact that some data is missing due to failure to pass
the threshold for data quality, in all cases a given chromosome can
be assigned unambiguously to one of the seven haplotypes. The four
most frequent haplotypes, each of which is represented by three or
more chromosomes, account for 80% of all chromosomes in the sample.
Only two "informative" SNPs out of the total of twenty-six are
required to distinguish the four most frequent haplotypes from one
another. In this example, four chromosomes with infrequent
haplotypes would be incorrectly classified as common haplotypes by
using information from only these two informative SNPs.
Nevertheless, it is remarkable that 80% of the haplotype structure
of the entire global sample is defined by less than 10% of the
total SNPs in the block. Several different possibilities exist in
which three informative SNPs can be chosen so that each of the four
common haplotypes is defined uniquely by a single SNP. One of these
"three SNP" choices would be preferred over the two SNP combination
in an experiment involving genotyping of pooled samples, since the
two SNP combination would not permit determination of frequencies
of the four common haplotypes in such a situation; thus, the
present invention provides a dramatic improvement over the random
selection method of SNP mapping.
[0200] In summary, while the particular application may dictate the
selection of informative SNPs to capture haplotype information, it
is clear that the majority of the haplotype information in the
sample is contained in a very small subset of all the SNPs. It is
also clear that random selection of two or three informative SNPs
from this block of SNPs will often not provide enough information
to uniquely assign a chromosome to one of the four common
haplotypes.
[0201] One issue is how to define a set of contiguous blocks of
SNPs spanning the entire 32.4 Mb of chromosome 21 while minimizing
the total number of SNPs required to define the haplotype
structure. In one embodiment, an optimization algorithm based on a
"greedy" strategy was used to address this problem. All possible
blocks of physically consecutive SNPs of size one SNP or larger
were considered. Ambiguous haplotype patterns were treated as
missing data and were not included when calculating percent
coverage. Considering the remaining overlapping blocks
simultaneously, the block with the maximum ratio of total SNPs in
the block to the minimal number of SNPs required to uniquely
discriminate haplotypes represented more than once in the block was
selected. Any of the remaining blocks that physically overlapped
with the selected block were discarded, and the process was
repeated until a set of contiguous, non-overlapping blocks that
cover the 32.4 Mb of chromosome 21 with no gaps, and with every SNP
assigned to a block, was selected. Given the sample size of twenty
chromosomes, the algorithm produces a maximum of ten common
haplotype patterns per block, each represented by two independent
chromosomes.
[0202] Applying this algorithm to the data set of 24,047 common
SNPs, 4135 blocks of SNPs spanning chromosome 21 were defined. A
total of 589 blocks, comprising 14% of all blocks, contain greater
than ten SNPs per block and include 44% of the total 32.4 Mb. In
contrast, 2138 blocks, comprising 52% of all blocks, contain less
than three SNPs per block and make up only 20% of the physical
length of the chromosome. The largest block contains 114 common
SNPs and spans 115 kb of genomic DNA. Overall, the average physical
size of a block is 7.8 kb. The size of a block is not correlated
with its order on the chromosome, and large blocks are interspersed
with small blocks along the length of the chromosome. There are an
average of 2.7 common haplotype patterns per block, defined as
haplotype patterns that are observed on multiple chromosomes. On
average, the most frequent haplotype pattern in a block is
represented by 9.6 chromosomes out of the twenty chromosomes in the
sample, the second most frequent haplotype pattern is represented
by 4.2 chromosomes, and the third most frequent haplotype patterns,
if present, is represented by 2.1 chromosomes. The fact that such a
large fraction of globally diverse chromosomes are represented by
such limited haplotype diversity is remarkable. The findings are
consistent with the observation that when haplotype pattern
frequency is considered, 82% of the haplotype patterns observed in
a collection of 313 human genes are observed in all ethnic groups,
while only 8% of haplotypes are population specific (Stephens, et
al., Science 293:489-93 (2001)).
[0203] Several experiments were performed to measure the influence
of parameters of the haplotype algorithm on the resulting block
patterns. The fraction of chromosomes required to be covered by
common haplotypes was varied, from an initial 80%, to 70% and 90%.
As would be expected, requiring more complete coverage results in
somewhat larger numbers of shorter blocks. Using only the 16,503
SNPs with a minor allele frequency of at least 20% in the sample
resulted in somewhat longer blocks, but the numbers of SNPs per
block did not change significantly. For one region of about 3 Mb, a
deeper sample of 38 chromosomes for SNPs and common haplotype
blocks with at least 10% frequency was analyzed, so as to be
comparable with the 20 chromosome analysis. The resulting
distribution of block sizes closely matched the initial results.
Also, a randomization test was performed in which the non-ambiguous
alleles at each SNP were permuted, and then used for haplotype
block discovery. In this analysis, 94% of blocks contained fewer
than three SNPs, and only one block contained more than five SNPs.
This confirms that the larger blocks seen in the data cannot be
produced by chance associations or as artifacts of the block
selection methods of the present invention.
[0204] In an effort to determine if genes were proportionately
represented in both large and small blocks, a determination was
made of the number of exonic bases in blocks containing more than
10 SNPs, 3 to 10 SNPs, and less than 3 SNPs. Exonic bases are
somewhat over-represented as compared to total bases in blocks
containing 3 to 10 SNPs (p<0.05 as determined by a permutation
test).
[0205] Based on knowledge of the haplotype structure within blocks,
subsets of the 24,047 common SNPs can be selected to capture any
desired fraction of the common haplotype information, defined as
complete information for haplotypes present more than once and
including greater than 80% of the sample across the entire 32.4 Mb.
FIG. 15 shows the number of SNPs required to capture the common
haplotype information for 32.4 Mb of chromosome 21. For each SNP
block, the minimum number of SNPs required to unambiguously
distinguish haplotypes in that block that are present more than
once (i.e., common haplotype information) was determined. These
SNPs provide common haplotype information for the fraction of the
total physical distance defined by that block. Beginning with the
SNPs that provide common haplotype information for the greatest
physical distance, the cumulative increase in physical coverage
(i.e., fraction covered) is plotted relative to the number of SNPs
added (i.e., SNPs required). Genic DNA includes all genomic DNA
beginning 10 kb 5' of the first exon of each known chromosome 21
gene and extending 10 kb 3' of the last exon of that gene. For
example, while a minimum of 4563 SNPs are required to capture all
the common haplotype information, only 2793 SNPs are required to
capture the common haplotype information in blocks containing three
or more SNPs that cover 81% of the 32.4 Mb. A total of 1794 SNPs
are required to capture all the common haplotype information in
genic DNA, representing approximately two hundred and twenty
distinct genes.
[0206] The present invention has particular relevance for
whole-genome association studies mapping phenotypes such as common
disease genes. This approach relies on the hypothesis that common
genetic variants are responsible for susceptibility to common
diseases (Risch and Merikangas, Science 273:1516 (1996), Lander,
Science 274:536 (1996)). By comparing the frequency of genetic
variants in unrelated cases and controls, genetic association
studies can identify specific haplotypes in the human genome that
play important roles in disease. While this approach has been used
to successfully associate single candidate genes with disease
(Altschuler, et al., Nature Genet. 26:76 (2000)), the recent
availability of the human DNA sequence offers the possibility of
surveying the entire genome, dramatically increasing the power of
genetic association analysis (Kruglyak, Nature Genet. 22:139
(1999)). A major limitation to the implementation of this method
has been lack of knowledge of the haplotype structure of the human
genome, which is required in order to select the appropriate
genetic variants for analysis. The present invention demonstrates
that high-density oligonucleotide arrays in combination with
somatic cell genetic sample preparation provide a high-resolution
approach to empirically define the common haplotype structure of
the human genome.
[0207] Although the length of genomic regions with a simple
haplotype structure is extremely variable, a dense set of common
SNPs enables the systematic approach to define blocks of the human
genome in which 80% of the global human population is described by
only three common haplotypes. In general, when applying the
particular algorithm used in this embodiment, the most common
haplotype in any block is found in 50% of individuals, the second
most common in 25% of individuals, and the third most common in
12.5% of individuals. It is important to note that blocks are
defined based on their genetic information content and not on
knowledge of how this information originated or why it exists. As
such, blocks do not have absolute boundaries, and may be defined in
different ways, depending on the specific application. The
algorithm in this embodiment provides only one of many possible
approaches. The results indicate that a very dense set of SNPs is
required to capture all the common haplotype information. Once in
hand, however, this information can be used to identify much
smaller subsets of SNPs useful for comprehensive whole-genome
association studies.
[0208] Those skilled in the art will appreciate readily that the
techniques applied to human chromosome 21 can be applied to all the
chromosomes present in the human genome. In a preferred embodiment
of the present invention, multiple whole genomes of a diverse
population representative of the human species are used to identify
SNP haplotype blocks common to all or most members of the species.
In some embodiments, SNP haplotype blocks are based on ancient SNPs
by excluding SNPs that are represented at low frequency. The
ancient SNPs are likely to be important as they have been preserved
in the genome because they impart some selective benefit to
organisms carrying them.
EXAMPLE 6
Using Associated Genes for Gene Therapy and Drug Discovery
[0209] One example for using the methods of the present invention
is outlined in this prophetic example. SNP discovery is performed
on twenty haploid genomes, and fifty haploid genomes are analyzed
by the methods of the present invention to determine SNP haplotype
blocks, SNP haplotype patterns, informative SNPs and minor allele
frequency for each informative SNP. These fifty haploid genomes
comprise the control genomes of the present study (see step 1300 of
FIG. 13).
[0210] Next, genomic DNA from 500 individuals having an obesity
phenotype are assayed for variants by using long distance PCR and
microarrays as described supra (see also, U.S. Pat. No. 6,300,063
issued to Lipshutz, et al., and U.S. Pat. No. 5,837,832 to Chee, et
al.), and the frequency of the minor allele for each informative
SNP is determined for this clinical population (see step 1310 of
FIG. 13). The minor allele frequencies of the informative SNPs for
the two populations are compared, and the control and clinical
populations are determined to have statistically significant
differences in three informative SNP locations (steps 1320 and
1330). The SNP location with the largest difference in the minor
allele frequency between the control and clinical populations is
selected for analysis.
[0211] The informative location selected is contained within a SNP
haplotype block that is found to span 1 kb of noncoding sequence 5'
of the coding region and 4 kb of the coding region of the leptin
gene (step 1340). Analysis of the variations contained within this
region indicates that a G at one SNP position in this region is
responsible for destruction of the promoter for the leptin gene,
with a commensurate lack of expression of the leptin protein.
[0212] Fibroblasts are obtained from a subject by skin biopsy. The
resulting tissue is placed in tissue-culture medium and separated
into small pieces. Small pieces of the tissue are placed on the
bottom of a wet surface of a tissue culture flask with medium.
After 24 hours at room temperature, fresh media is added (e.g.,
Ham's F12 media, with 10% FBS, penicillin and streptomycin). The
tissue is then incubated at 37.degree. C. for approximately one
week. At this time, fresh media is added and subsequently changed
every several days. After an additional two weeks in culture, a
monolayer of fibroblasts emerges. The monolayer is trypsinized and
scaled into larger flasks.
[0213] The vector derived from the Moloney murine leukemia virus,
which contains a kanamycin resistance gene, is digested with
restriction enzymes for cloning a fragment to be expressed. The
digested vector is treated with calf intestinal phosphatase to
prevent self-ligation. The dephosphorylated, linear vector is
fractionated on an agarose gel and purified. Leptin cDNA, capable
of expressing active leptin protein product, is isolated. The ends
of the fragment are modified, if necessary, for cloning into the
vector. Equal molar quantities of the Moloney murine leukemia virus
linear backbone and the leptin gene fragment are mixed together and
joined using T4 DNA ligase. The ligation mixture is used to
transform E. Coli and the bacteria are then plated onto
agar-containing kanamycin. Kanamycin phenotype and restriction
analysis confirm that the vector has the properly inserted leptin
gene.
[0214] Packaging cells are grown in tissue culture to confluent
density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf
serum, penicillin and streptomycin. The vector containing the
leptin gene is introduced into the packaging cells by standard
techniques. Fresh media is added to the packaging cells, and after
an appropriate incubation period, media is harvested from the
plates of confluent packaging cells. The media, containing the
infectious viral particles, is filtered through a Millipore filter
to remove detached packaging cells, then is used to infect
fibroblast cells. Media is removed from a sub-confluent plate of
fibroblasts and quickly replaced with the filtered media. Polybrene
(Aldrich) may be included in the media to facilitate transduction.
After appropriate incubation, the media is removed and replaced
with fresh media. If the titer of virus is high, then virtually all
fibroblasts will be infected and no selection is required. If the
titer is low, then it is necessary to use a retroviral vector that
has a selectable marker, such as neo or his, to select out
transduced cells for expansion.
[0215] Engineered fibroblasts then are introduced into individuals,
either alone or after having been grown to confluence on
microcarrier beads, such as cytodex 3 beads. The injected
fibroblasts produce leptin product, and the biological actions of
the protein are conveyed to the host.
[0216] Alternatively or in addition, the leptin gene is isolated,
cloned into an expression vector and employed for producing leptin
polypeptides. The expression vector contains suitable
transcriptional and translational initiation regions, and
transcriptional and translational termination regions, as disclosed
supra. Isolated leptin protein can be produced in this manner and
used to identify agents which bind it; alternatively cells
expressing the engineered leptin gene and protein are used in
assays to identify agents. Such agents are identified by, for
example, contacting a candidate agent with an isolated leptin
polypeptide for a time sufficient to form a polypeptide/compound
complex, and detecting the complex. If a polypeptide/compound
complex is detected, the compound that binds to the leptin
polypeptide is identified. Agents identified via this method can
include compounds that modulate activity of leptin. Agents screened
in this manner are peptides, carbohydrates, vitamin derivatives,
and other small molecules or pharmaceutical agents. In addition to
biological assays to identify agents, agents may be pre-screened by
choosing candidate agents selected by using protein modeling
techniques, based on the configuration of the leptin protein.
[0217] In addition to identifying agents that bind the leptin
protein, sequence-specific or element-specific agents that control
gene expression through binding to the leptin gene are also
identified. One class of nucleic acid binding agents are agents
that contain base residues that hybridize to leptin mRNA to block
translation (e.g., antisense oligonucleotides). Another class of
nucleic acid binding agents are those that form a triple helix with
DNA to block transcription (triplex oligonucleotides). Such agents
usually contain 20 to 40 bases, are based on the classic
phosphodiester, ribonucleic acid backbone, or can be a variety of
sulfhydryl or polymeric derivatives that have base attachment
capacity.
[0218] Additionally, allele-specific oligonucleotides that
hybridize specifically to the leptin gene and/or agents that bind
specifically to the variant leptin protein (e.g., a
variant-specific antibody) can be used as diagnostic agents.
Methods for preparing and using allele-specific oligonucleotides
and for preparing antibodies are described supra and are known in
the art.
[0219] All patents and publications mentioned in this specification
are indicative of the levels of those skilled in the art to which
the invention pertains. All patents and publications are herein
incorporated by reference to the same extent as if each individual
publication was specifically and individually indicated to be
incorporated by reference.
[0220] The present invention provides greatly improved methods for
conducting genome-wide association studies by identifying
individual variations, determining SNP haplotype blocks,
determining haplotype patterns and, further, using the SNP
haplotype patterns to identify informative SNPs. The informative
SNPs may be used to dissect the genetic bases of disease and drug
response in a practical and cost effective manner unknown
previously. It is to be understood that the above description is
intended to be illustrative and not restrictive. Many embodiments
will be apparent to those skilled in the art upon reviewing the
above description. The scope of the invention should, therefore, be
determined not with reference to the above description, but should
instead be determined with reference to the appended claims, along
with the full scope of equivalents to which such claims are
entitled.
Sequence CWU 1
1
8 1 13 DNA Artificial Sequence Hypothetical sequence 1 agattcgata
acg 13 2 13 DNA Artificial Sequence Hypothetical Sequence 2
agactacata acg 13 3 13 DNA Artificial Sequence Hypothetical
Sequence 3 tatttcgata acg 13 4 13 DNA Artificial Sequence
Hypothetical Sequence 4 tatctacaat cac 13 5 13 DNA Artificial
Sequence hypothetical sequence 5 actgacccct ttt 13 6 13 DNA
Artificial Sequence Hypothetical Sequence 6 agtaacccct ttt 13 7 13
DNA Artificial Sequence Hypothetical Sequence 7 actgacccct ttt 13 8
13 DNA Artificial Sequence Hypothetical Sequence 8 agtgactctt taa
13
* * * * *
References